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Abstract
In this study, we explore the molecular mechanisms linking amino acid (leucine)
deprivation to IGFBP-1 hyperphosphorylation in vitro. During pregnancy, a maladaptive
fetal response to in utero amino acid deprivation leads toFetal Growth Restriction (FGR).
FGR infants display elevated phosphorylatedIGFBP-1, which is associated with
decreased IGF-I bioavailability. Leucine deprivation inhibits mechanistic target of
rapamycin (mTOR) signaling and stimulates the amino acid response (AAR). Using
HepG2 cells, a model for fetal hepatocytes, we demonstrate that in leucine deprivation,
the AAR modulates total and phosphorylated IGFBP-1 while mTOR mediates total
IGFBP-1 secretion only. We also reveal that protein kinases CK2 and PKC mediate
IGFBP-1 phosphorylation and subsequent IGF-I bioactivity in leucine deprivation.
Together, our findings implicate fetal hepatic AAR and CK2 activation as key
mechanistic links between amino acid deprivation and decreased IGF-I bioavailability in
FGR and suggest a novel role for PKC in modulating IGFBP-1 phosphorylation in vitro.
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Chapter 1

1 Introduction
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1.1 Fetal Growth Restriction (FGR)
1.1.1 Definition, diagnosis and outcomes
Fetal Growth Restriction (FGR) is a perigestational growth disorder whereby the fetus
fails to achieve its full, genetically-determined growth potential, and is linked to an
increased risk of neonatal death as well as several perinatal and adult morbidities1,2.
Affecting 5-7% of pregnancies3, FGR infants are born under the 10th percentile birthweight expected for gestational age4, though some more stringent definitions classify
FGR infants as those born under the 5th or 3rd percentiles5 of expected birth-weight. FGR
infants are notoriously difficult to identify among small for gestational age (SGA) babies
– a classification accorded to all neonates born under the 10th percentile expected birthweight, including those who are healthy and constitutively small due to factors such as
ethnicity, sex, and body/mass index and those infants affected by other growth-restricting
pathologies. In fact, 70% of SGA infants are at no increased risk for perinatal or adult
morbidity6. There are presently no reliable tools for the diagnosis and management of
FGR7 among SGA infants. Currently, likelihood of FGR onset is determined prenatally
based on suspicion of maternal risk factors, followed by clinical assessments of various
maternal aspects (e.g. maternal abdominal circumference, amniotic fluid volume, and
estimated fetal weight) as well as sonographic screening of the fetus7,8. Uterine arterial
Doppler velocimetry is a useful measure of placental function, as it indicates blood flow
between the fetus and placenta9, and Doppler values of the umbilical artery, in addition to
fetal heart rate, are useful in detecting the fetal cardiac manifestations of FGR7,10.
However, clinically, these tools have been proven to be highly unreliable in consistently
predicting FGR7, 9, 11 and therapeutic strategies against FGR have also been ineffective12.
The importance of perigestational influences on the development of adult diseases is
becoming increasingly recognized in a paradigm known as the “developmental origins of
health and disease” or “fetal programming”13,14. Indeed, FGR is associated with perinatal
mortality and morbidity1,15 as well as severe adult neurological, metabolic, and
cardiovascular complications1,2,15-17, even for infants who have achieved post-natal
“catch-up growth”18. The lifetime implications of FGR for the individual patient, and the
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subsequent implications of the disorder on public health system, make it an important
area for investigation.

1.1.2 Insufficient placental nutrient (amino acid) transfer in FGR
The underlying etiologies of FGR are diverse: fetal genetics, perigestational viral
infections, and disturbances in maternal health account for 30-50% of FGR cases19-21.
However, the majority of FGR incidences are attributed to placental factors which
compromise the ability of the placenta to adequately transfer nutrients from the mother to
the fetus during pregnancy4,22,23. Perigestational nutritional supply is a dominant
influence on the fetal programming of adult diseases387,388. The adequate availability of
nutrients to the fetus is directly linked to fetal growth and is dependant on adequate
placental function389.
As the feto-maternal interface, adequate placental function is essential in controlling
appropriate resource allocation between mother and fetus, which is integral to
reproductive success. The placenta matures during pregnancy to meet increasing fetal
nutritional demands10, which intensify as fetal growth rate increases over the course of
gestation with the fetus experiencing maximum overall growth during the third
trimester24. Pathological placental function, such as due to abnormal placental
angiogenesis leading to decreased utero-placental blood flow, decreases placental
capacity for nutrient transfer25,26. Both mother and fetus physiologically adapt to
fluctuations in nutrient availability based on nutritional cues derived from the placenta13,
and placental function itself is metabolically consuming and dependent on hormonal cues
from both the mother and fetus27,28. Evidence is emerging for placental nutrient sensing
as a key factor in healthy fetal growth13, suggesting that the placenta serves as much more
than a passive conduit for nutrients from the mother to fetus. Placental nutrient sensing
involves a complex of signaling mechanisms which serve to integrate nutritional cues
from both mother29-34 and fetus27,35-38 to regulate nutrient transportin an effort to optimize
both maternal and fetal outcomes13,39. Insufficiency in any aspect of this process which
results in the fetus not receiving the appropriate quantity of nutrients, such as essential
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amino acids, necessary for its healthy development can trigger a maladaptive fetal
response leading to FGR40,41.
Excess amino acids are not stored in humans54, so the developing fetus requires a
constant, reliable supply of essential amino acids (EAAs) from the placenta in order to
sustain fetogenesis. Of the 20 amino acids, nine (leucine, isoleucine, valine, lysine,
threonine, tryptophan, phenylalanine, methionine, histidine) are considered “essential” as
they are not internally synthesized54. Decreased fetal/maternal “enrichment” ratios of
various EAAs – which areindicative of reduced trans-placental EAA transport – have
been detected in FGR pregnancies46-48. This is largely due to the down-regulated
expression of placental amino acid transporters (System L (leucine) transporter, Taurine
transporter (TAUT), and System A transporter) in FGR22,49-52. Inadequate placental
function leads to increased amino acid concentrations in the maternal circulation and
decreased circulating amino acids in the fetuses of FGR pregnancies42. Induced FGR via
placental embolization in an ovine model reduced fetal plasma and amniotic fluid
concentrations of all amino acids by 15%43, and altered amino acid profiles are observed
in the plasma of women who experience FGR versus healthy
pregnancies44.Maladaptative responses by the fetus to perigestational amino acid
deficiency likely induce a host of developmental complications, including FGR53.

1.1.3 Fetal response to deficient nutrient (amino acid) supply
Decreased fetal amino acid uptake is characteristic of FGR55 and fetal circulating EAAs
are decreased in growth-restricted fetuses4. The ability of a single EAA, leucine, to
attenuate induced FGR45 suggests that amino acid availability is implicated in FGR
pathogenesis. Bajoria et. al. assessed amino acid plasma concentrations at birth in human
twins who experienced discordant growth, where one infant was FGR and one was
appropriate for gestational age (AGA)56. The FGR twin demonstrated decreased plasma
venous EAAs, especially the branched-chain amino acids (BCAAs – leucine, isoleucine,
valinel) compared to the AGA twin56. Teodoro et. al. demonstrated that amino acid
supplementation of maternal-protein-restricted rats restored growth and organ mass in
offspring45, which were otherwise reduced by restricted maternal diets.
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In the fetus, an intrinsic maladaptive response after suffering amino acid deprivation
likely manifests in FGR53. Fetuses are highly sensitive to fluctuations in circulating
maternal amino acid availability – in fact, 48 hours of restricted maternal protein intake
was sufficient to produce growth-restricted offspring in a mouse model57. Maternal
fasting led to decreased insulin, increased glucagon and potentiated activity of key
gluconeogenic factors in the livers of growth-restricted rats57. Girard et. al. demonstrated
that decreased nutrient supply from the mother during the third trimester induces
premature fetal gluconeogenesis, likely leading to impaired fetal growth at the cost of
endogenous fuel provision57. The need for the fetus to endogenously provide energy in
amino acid-restricted conditions is further demonstrated by the observation that
diminished placental amino acid transfer elicits increased fetal protein catabolism, as
observed via increased concentrations of certain fetal tissue amino acids, and concomitant
placental dysfunction, in human FGR28,58,59.
There is strong evidence that the fetal response to amino acid unavailability in
uteroinflicts long term repercussions on offspring health in addition to confining fetal
growth7,45,56,60. In an experimental model for FGR, pregnant rats fed nutrient restricted
diets exhibited significantly decreased circulating levels of the three essential BCAAs,
which led to FGR in off-springs and correlated to severe glucose intolerance and
atherosclerosis in adult life60. In approximately 70-80% of human FGR infants61,62, the
metabolic stress due to amino acid insufficiency causes the fetus to prioritize its limited
energy supply towards preserving the functions of vital organs such as the heart, brain
and placenta at the compromise of the full maturation of remaining fetal organs63-67,
which frequently leads to asymmetrical fetal growth61,62. These FGR infants are typically
born with larger head:body mass ratios7, and compromised maturation of fetal organs –
including the brain68 – which likely manifests in its compromised function later in life.
The specific signaling pathways triggered in the fetus upon amino acid restriction which
serve to link amino acid deprivation to decreased fetal growth in the FGR fetus remain
largely elusive. Fetogenesis is a dynamic and molecularly complex phenomenon that
involves the interaction of a variety of signaling pathways, abrogation of any of which
may lead to deterred fetal growth and development. By elucidating the molecular
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mechanisms linking amino acid deprivation to restricted fetal growth, we will further our
understanding of FGR pathogenesis, which is quintessential in the future development of
targeted therapies and diagnosis against the disorder that are currently lacking.

1.2

The Insulin-like Growth Factors (IGFs) in Fetal

Growth and Development
To explore the mechanisms modulating fetal growth under amino acid restriction, we
focused our attention on the key mediators of fetal growth and development. The Insulinlike Growth Factor (IGF)/IGF-Binding Protein(IGFBP) axis is critically involved in fetal
cell growth and proliferation. During human pregnancy, the two IGFs (IGF-I, IGF-II)
are synthesized by most embryonic and fetal tissues and play important roles in fetal
growth69-71. As gestation progresses, IGF production increases 72 and as the fetal liver
develops, the majority of IGF is hepatically synthesized 73 and secreted into the fetal
circulation74,75 where it contributes to systemic fetal growth and development 76.
The two IGFs have unique and shared functions in fetogenesis. Both IGFs are
synthesized by in early gestation77 and are necessary for the migration of trophoblast cells
in the maternal decidua78 which is crucial to healthy placental and fetal development.
Fetal liver secretes IGF-II protein whose mRNA is transcribed from the paternally
imprinted allele79with mRNA detection as early as 12-18 days gestation. Deficits in IGFII signaling during early embryo development typically result in irregular organogenesis
and fetal demise80. For example, it has been shown that mice null for IGF-II displayed
pathological placental and embryonic growth37. IGF-II exists in the fetal serum in far
greater concentrations (3-10 fold) than IGF-I72,81, and this imbalance persists post-natally
in humans where IGF-II is typically present in a 2.5-fold greater concentration in serum
compared to IGF-I.
However, as gestation progresses, fetal development becomes increasingly dependent on
IGF-I82. Unlike IGF-II, which has been proposed to provide continuous stimulus for
growth81, IGF-I activity is more sensitive to physiological and environmental cues, such
as nutritional stress81,83. Fetal IGF-I secretion begins early in gestation (~6 weeks)72 by all
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fetal tissues and at this time, functions primarily in an autocrine/paracrine manner84. IGFI secretion rises dramatically around 16-20 weeks gestation85 as the fetal liver matures,
and continues to increase systemically throughout the remaining gestational
period72,75,85,86. Both the endocrine and paracrine functions of IGF-I become increasingly
critical to the development of fetal tissues as gestation progresses87. During this period,
IGF-I levels in cord serum of healthy fetuses rise to 10-80 ug/L85, and only begin to
decrease post-natally72. IGF-I is the key mediator of overall fetal growth88-91, particularly
in the third trimester68,92,93 when it is the dominant regulator of organ maturation80,94.
Fetal circulating IGF-I levels have been consistently and positively associated with infant
birth-weight82,86. In the fetal brain, IGF-I signaling is critically involved in neurogenesis,
synaptogenesis, and myelination66,67.
Wang et. al. have suggested that IGF-I is synthesized separately in the mother and fetus
and that the mitogen does not cross the placenta95. In concordance, Davenport et. al.
reported a limited ability of IGF-I to transverse the placental barrier96. However, Bassett
et. al. showed that the placenta expresses the cognate receptor of IGF-I (IGF-1 Receptor)
and that fetal IGF-I levels are radically modulated by the placenta in late gestation97.
Further, maternal and fetal IGF-I feedback to acutely influence placental function, as
indicated by the ability of IGF-I to influence amino acid allocation between the maternal
and fetal compartments via the placenta82,98,99. Together, these studies emphasize the
importance of available IGF-I in the fetal compartment in regulating fetal development
and illustrate the dynamic interplay between placental nutrient sensingand IGF signaling
in influencing fetal growth.

1.2.1 Structural basis of IGF-I function via its receptor (IGF-1R)
The IGFs are mitogenic proteins that exist as single polypeptide chains, are highly
conserved among species and are structurally and functionally homologous to insulin120122

. The tertiary IGF-I molecule contains a hydrophobic core similar to insulin in addition

to a 12-residue connecting peptide, and a carboxy-terminal extension123. The IGFs and
insulin share common ancestral history124,125; however, their functions have largely
diverged over the course of evolution124,125. Unlike insulin, whose primary function is
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metabolic regulation, the key function of the IGFs is to modulate cell growth and
proliferation126. The IGFs participate directly in cell growth, metabolism, and
proliferation126,127 in both pre- and post-natal life by binding to their ubiquitinouslyexpressed cell-surface receptor, IGF-1 Receptor (IGF-1R)122,126.
IGF-1R is structurally homologous to the insulin receptor (IR) (58% sequence
identity)128. However, unlike the IRwhich participates primarily in glucose and lipid
metabolism, IGF-1R activity is primarily associated with cell growth and
differentiation129. IGF-1R is a heterotetrameric protein that contains two α subunits
containing the extracellular ligand-binding domain, and two disulfide bond-liked β
subunits with tyrosine kinase activity130. The extra-cellular domain maintains IGF-1R in
an inactive state until ligand binding131, upon which a conformational change induces
IGF-1R autophosphorylation at the two β subunits (pTyr1135), thereby activating the
receptor131. IGF-1R β phosphorylation is necessary and sufficient for its activation131 and
subsequent initiation of secondary messenger cascades which stimulate downstream
mitogenic responses such as increased protein translation, proliferation and anti-apoptotic
activity122,130,132.
IGF-1R is the primary receptor for IGF-I and its activity has been shown to be critically
involved in fetal development105,136,137. Mice null for IGF-1R weigh 45% of control birth
weight perinatally and experience a high mortality rate, supporting that IGF-1R activity is
a key factor affecting fetal development105. To a lesser degree, IGF-I and IGF-II can also
stimulate IR and IGF-I/insulinhybrid receptor (HR)138. IGF-II also binds to IGF-2R,
which functions only to sequester IGF-II and attenuate its mitogenic effects. Expression
of both receptors is regulated based on environmental stimuli and dependent on the
immediate needs of the organism.

1.2.2 IGF-I in FGR
Although IGF-II is more abundant in fetal circulation72,100-102, only fluctuations in IGF-I
bioavailability have been consistently associated with FGR101,102. In an experimental
model, IGF-II overexpression in mice was unable to rescue stunted growth induced by

9
IGF-I depletion104. Analysis of human fetal cord blood demonstrates that FGR fetuses
display decreased circulating, bioavailable IGF-I76,88,101-103. Further, knockdown mice
deficient in IGF-I display decreased fetal weight and increased neonatal death in
addition to aberrant post-natal development and cognitive deficits reminiscent of
FGR91,105. Growth-restricted neonates in ovine and murine models of FGR demonstrate
decreased placental and fetal sensitivity to IGF-I63,106,107. One study has demonstrated
extremely stunted growth in a severe FGR human patient with a deletion in the gene
encoding IGF-I115.
Placental IGF-I expression is reduced in mouse models of FGR108 and in human FGR
infants109,110. Further, IGF-I protein levels are decreased in the circulation of mothers
delivering FGR babies compared to maternal plasma from healthy pregnancies111,112and
in their FGR infants at term 113.Conversely, malnourished human mothers who produce
significantly more small for gestational age (SGA) and FGR neonates secrete higher
levels of total IGF-I (free and bound), suggesting an adaptive maternal response to in
utero nutrient restriction114. IGF-I levels are highly sensitive to nutrient
availability83,97,116,117; in particular, it has been suggested that nutritional status in the
second half of gestation affects fetal circulating IGF-I concentrations83,88 . Perigestational
maternal under-nutrition leads to decreased IGF-I in the fetus in late gestation117.IGF-I
levels, in turn, are positively correlated with infant birth-weight95,119.
Although total IGF-I levels rise dramatically as gestation progresses72, its bioavailability
is contingent on developmental period, subject to tissue specificity and is highly
sensitive to nutrient status 83. Modulation of IGF-I bioavailability rather than total
endogenous levels is critical to the regulation of fetal growth. For example, increased
methylation of the IGF-I gene correlated to decreased total plasma IGF-I, but this
decrease in IGF-I expression was not correlated with the FGR phenotype in an ovine
model86. Based on the evidence provided, it is ascertainable that reduced IGF-I
bioactivity is a hallmark of FGR.
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1.3

Regulation of IGF-I bioavailability by the IGF

binding proteins (IGFBPs)
Total IGF is abundant in circulation; however, its bioavailability is tightly regulated by
the six IGF binding proteins (IGFBP-1-6)139,140. IGFBPs are secretory proteins that
modulate IGF bioactivity by binding the mitogenic proteins in various extracellular
compartments 141. The six IGFBPs serve to regulate the distribution of IGFs between
the circulation, tissue fluids, and cell surface binding sites, thereby tightly
controlling IGF bioavailablity 139. The majority of IGFs (>90%) typically exist in
circulation bound to IGFBPs132,385,386. Each of the six binding proteins differently
regulates IGF bioactivity, as they bind and sequester IGFs from their receptors with
varying affinities and with varying functions such as to prolong their half-lives, attenuate
their bioactivity, maintain them in circulation, or to target them to specific tissues142.

1.3.1 IGFBP-3 is the general transport protein for IGF-I
Most IGF protein exists in circulation bound to IGFBP-3 in a stable, ternary complex
with acid labile subunit (ALS) glycoprotein143,144. IGFBP-3 actions are generally growthpromoting, functioning to prolong the half-lives of and effectively transport both IGF-I
and IGF-II throughout the circulation. The IGFBP-3:IGF-I:ALS complex has a half-life
of 12 hours, which is significantly extended compared to free unbound IGF-I (t1/2 = 10
minutes) or IGFBP-3 (t1/2 = 30-90 minutes)143. At any given time, IGFBP-3 is associated
with approximately 75% of total IGF, maintaining a reservoir of IGFs within the
circulation either free or bound to other IGFBPs, available for immediate metabolic
demands143.
IGFBP-3 is the predominant circulating IGFBP in post-natal life at approximately a 10time higher concentration than other IGFBPs145. Accordingly, IGFBP-3 serves as the
major IGF transport protein while other IGFBPs are involved in more specific, acute
regulation of IGF bioactivity145. Although IGFBP-3 sequesters the majority of total IGFI, the role of this binding protein is generic and generally stable in circulation.
Fluctuations in IGFBP-3 levels have not been found to be consistently associated with
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disease states. In contrast, the roles of other IGFBPs are more specific. IGFBP-1 plays a
crucial role in mitogen signaling in ovarian, endometrial, trophoblast and fetal and
placental tissues146 and is the key circulating IGFBP during gestation75.

1.3.2 IGFBP-1 regulation of IGF-I during pregnancy
Hepatically secreted IGFBP-1 is a potent inhibitor of the IGFs both in vitro147 and in
vivo148-150,186,187. However, IGFBP-1 has a much greater affinity for IGF-I compared to
IGF-II151, supporting its role as a potent, specific inhibitorof IGF-I bioavailability.
IGFBP-1 regulates free serum IGF-I bioavailability154 by binding and sequestering IGF-I
from IGF-1R, preventing it from transducing its growth-promoting effects155-159. IGFBP1 has been suggested to bind to IGF-I and block its receptor-binding site160.
IGFBP-1 is the predominant circulating IGFBP in fetal circulation, fetal liver, placenta
and amniotic fluid during pregnancy69,74,103,149,152,153. IGFBP-1 is significantly elevated in
pregnant versus non-pregnant women (approx. 2-fold) and is present at even higher
concentrations in amniotic fluid161. During pregnancy, decidual cells secrete IGFBP-1
into the placenta162,163 where it functions primarily to inhibit trophoblast invasion at the
placental barrier, which is involved in embryo implantation164. In the fetal compartment,
IGF-I bioavailability is tightly regulating by fetal hepatic IGFBP-1 which is widely
acknowledged as a critical factor in altered human fetal development12, 54, 66, 67, 175, 193.
Fetal liver is the primary source of fetal IGFBP-1175 and fetal hepatic IGFBP-1 is the
primary regulator of fetal IGF-I bioactivity76.
Fetal IGFBP-1 levels rise dramatically around approximately 16-20 weeks gestation and
rapidly reach their peak72. IGFBP-1/IGF-I binary complexes increase in tandem with fetal
IGFBP-1 production at 16 weeks gestation72. Once the concentration of IGFBP-1 peaks,
it remains at a steady concentration for the remaining gestational period in both the
fetus72and maternal plasma176 in normal, non-growth restricted pregnancies. Langford et.
al. determined a steady concentration of 300 +/- 25.1 ug/L IGFBP-1 in healthy fetuses,
which remained consistent throughout gestation85. In the fetus, IGFBP-1 levels fall after
33 weeks gestation and continue decreasing post-natally95.
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1.3.3 IGFBP-1 structural elements
The Igfbp1 gene is located adjacent to Igfbp3 on chromosome 7p12-p14 177.The
IGFBP-1 promoter contains the TATA element in addition to a cAMP response
element (CRE), glucocorticoid response elements 1 (GRE1) and 2 (GRE2), and
binding sites for hepatic nuclear factor 1(HNF1) and 3 (HNF3), the latter also known
as the insulin-response element (IRE) 154. Binding to the HNF1 motif on the IGFBP-1
promoter contributes to tissue-specific expression of IGFBP-1 in the decidua, ovary,
liver and kidney154. Systemically, insulin is the primary regulator of IGF-I
transcription via binding to the IRE and subsequent inhibition of IGFBP-1
transcription, whereas glucocorticoids and cAMP stimulate IGFBP-1 expression154.
The six IGFBPs possess several structural and functional similarities particularly in their
highly conserved, cysteine-rich, amino- and carboxy-terminal domains178. The primary
IGFBP sequence contains a string of 12 N-terminal and six C-terminal cysteines, which
have been demonstrated to be necessary for optimal IGF binding and are conserved
among all IGFBPs in mammalian systems179. The di-sulfide bonds in these highly
conserved N- and C- terminal cysteine residues form a highly specific IGF-binding
pocket178,180. Conversely, the linker region between the two terminal domains is
mobile and not well conserved among the IGFBPs. The linker region contains sites
for post-translational modification, protein/protein interactions, and ubiquitination
that are unique to each IGFBP 139,156,181,182 . This linker region is prone to
phosphorylation in IGFBP-1, -3, and 5140, however, only phosphorylation of IGFBP-1
in this region enhances its affinity for IGF-I166,183,184and its ability to inhibit IGF
bioactivity155-158,185 .

1.3.4 IGFBP-1 phosphorylation
Phosphorylation of IGFBP-1 dramatically increases its affinity for IGF-I73,151 and
potentiates its bioinhibitory effect on the mitogen73,139,151,155. IGFBP-1 phosphorylation is
associated with the inhibition of IGF-I-mediated cell proliferation, amino acid
transport and apoptosis 155. Phosphorylated IGFBP-1 has also been shown to inhibit
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IGF-I-stimulated DNA synthesis in experimental animals 156, smooth muscle cells 185
and fetal skin fibroblasts 157.
Previously, our team has demonstrated that IGFBP-1 hyperphosphorylation is associated
with decreased IGF-I bioavailability in amniotic fluid from FGR pregnancies171and with
decreased IGF-I bioactivity in vitro172,173. Our lab has also previously demonstrated that
IGFBP-1 hyperphosphorylation is indicative of decreased IGF-I bioavailability in vitro
by demonstrating a link between increased IGFBP-1 phosphorylation and decreased IGF1R autophosphorylation in HepG2 cells172. Phosphorylated IGFBP-1 secreted by HepG2
cells displays a 6-fold higher affinity for IGF-I compared to non-phosphorylated
IGFBP-173, and hyperphosphorylated IGFBP-1 species derived from human plasma
displays approximately 10-fold greater binding affinity for IGF-I151. Interestingly,
IGFBP-1 phosphorylation does not affect its propensity for IGF-II binding153.
Sites of IGFBP-1 phosphorylation
Mass spectrometry has helped identify five phosphorylation sites on IGFBP-1
(Ser95, Ser98, Ser101, Ser119, Ser169) 158. The phosphorylation status of IGFBP-1 at
Ser101, Ser119 and Ser169 has been associated with altered IGF-I affinity73,190,191 and
IGF-I bioactivity in vitro172.Jones et. al. demonstrated that site-directed mutagenesis
of Ser101 to un-phosphorylatable Ala101 decreases IGFBP-1 affinity for IGF-I 3fold183. By mutating phospho-acceptor residues to un-phosphorylatable Ala residues
in HepG2 cells, our team has demonstrated that phosphorylation of IGFBP-1at
Ser101, Ser119 and Ser169 variably affects IGF-I bioavailability, with most
pronounced effects when IGFBP-1 was mutated to Ser101Ala and Ser119Ala 172.
Ser101, Ser119 and Ser169 are sensitive to phosphorylation in vitro in response to
leucine restriction and are associated with potent increases in IGF-I affinity (up to 30fold) upon phosphorylation190.Our lab has previously demonstrated an increase in
pSer101, pSer119 and pSer169 in amniotic fluid171 and umbilical cord plasma173 from
FGR babies as well as in fetal hepatocytes from a baboon model of FGR173.
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6-10-fold greater affinity
IGF-I

Figure 1.1.IGFBP-1 sequesters IGF-I from its cell surface receptor. Phosphorylated
IGFBP-1 sequesters IGF-I with greater affinity.

1.3.5 Total and phosphorylated IGFBP-1 in normal and growthrestricted pregnancies
Total IGFBP-1 and fetal growth
Several groups have linked FGR with increased fetal IGFBP-156,93,95,103,112,160,192,194-196
FGR infants have been shown to have increased perigestational cord blood93,95,160,194 and
post-natal circulating195,196 IGFBP-1. Elevated IGFBP-1 in maternal plasma95,197 and
placental tissues112,113 are also inversely related to infant birth weight. A study on
discordant twins (one FGR and one AGA infant) demonstrated increased IGFBP-1 in
FGR infants compared to their AGA siblings, a difference that was not observed in twin
pairs who experienced concordant growth56. This finding suggests that altered IGFBP-1
levels in FGR are likely due to environmental, rather than genetic, influences.
Additionally, transgenic over-expression of IGFBP-1 in murine fetuses decreased fetal
birth weight by 18%175, suggesting a causative relationship between IGFBP-1 and
restricted fetal growth. HepG2 cells cultured in leucine concentrations observed in
nutrient-restricted rats had significantly induced IGFBP-1 mRNA and protein
expression198. Further, Bajoria et. al. reported that fetal IGFBP-1 production was elevated
in FGR infants where amino acid supply was reduced56. The negative correlation between
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fetal amino acid uptake and IGFBP-1 production suggests that increased IGFBP-1
synthesis may be a fetal response to decreased amino acid availability.
IGFBP-1 phosphorylation and fetal growth
Fetal liver contains an abudance of phosphorylated IGFBP-1 throughout the gestational
period162. Conversely, IGFBP-1 phosphorylation in the maternal compartment appears to
be temporally regulated. Amniotic fluid IGFBP-1 circulates primarily unphosphorylated
in early pregnancy with singly and multiply phosphorylated IGFBP-1 present in
decreasing concentrations158, although the exact proportions of total to unphosphorylated
IGFBP-1 have not been classified. However, as pregnancy progresses, the relative
abundance of highly phosphorylated IGFBP-1 species increases in maternal plasma162,
placenta162 and amniotic fluid168.
The partially and highly phosphorylated IGFBP-1 isolated from cord plasma likely
originates in the fetal liver169. Fetal IGF-I levels continue to rise throughout pregnancy
while IGFBP-1 levels, once peaked, typically remain consistent for the remaining
gestational period72. It is likely that IGFBP-1 phophorylation is a cellular mechanism
employed to fine-tune IGF-I bioavailability, and that increased phosphorylation of
IGFBP-1 rather than its total secreted levels is the principal regulator of IGF-I
bioavailability in latter gestation.
Altered IGFBP-1 phosphorylation is associated with fetal abnormalities165,171,173,174,189,199.
Phosphorylated IGFBP-1 is elevated in cord plasma of growth restricted babies relative to
babies who are appropriate for gestational age (AGA)165, with an accompanied decreased
proportion of non-phosphorylated IGFBP-1 in these infants. Further, amniotic fluid from
FGR pregnancies also displays an altered phospho-isoform profile for IGFBP-1compared
to amniotic fluid from healthy pregnancies191. IGFBP-1 hyperphosphorylation at
specific phosphosites (Ser101, Ser119 and Ser169) was previously detected by our
team in amniotic fluid 171 and umbilical cord plasma 173 from FGR pregnancies. Our
team also previously reported that hyperphosphorylation of IGFBP-1 at pSer101 and
pSer169 in amniotic fluid is most dramatically increased in FGR 171, but that
hyperphosphorylation at Ser119 most potently induces IGFBP-1 affinity for IGF-I191.
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In addition, we recently reported IGFBP-1 hyperphosphorylation at pSer101,
pSer119, and pSer169 in umbilical cord plasma of FGR babies as well as fetal
baboon hepatocytes from nutrient-restricted mothers 173. In contrast, in human
amniotic fluid, a decreased ratio of highly phosphorylated to lowly phosphorylated
IGFBP-1 isoforms is linked with stimulated fetal growth 200.
In summary, the literature suggests that diminished amino acid supply to the fetus during
gestation is a key factor in FGR onset, and that IGFBP-1 hyperphosphorylation leads to
decreased IGF-I bioavailability. However, the signaling mechanisms involved in
signaling amino acid deficiency to increased fetal hepatic IGFBP-1 phosphorylation are
presently unknown. Herein, we explore candidate nutrient-sensing signaling pathways for
their potential role in modulating hepatic IGFBP-1 secretion and phosphorylation in
amino acid deprivation.

1.4

Nutrient-sensing signaling pathways

Nutrient deprivation is an environmental stressor, requiring an adaptive cellular response
to optimize organismal outcomes. Upon nutritional stress, the organism typically defends
overall homeostasis by reducing cell growth and survival and promoting energy
conservation201. The mechanistic target of rapamycin (mTOR) and Amino Acid Response
(AAR) are key sensors of nutrient (amino acid) availability in several cell types202,203
including the liver203. Here, we highlight the functions of these two signaling pathways in
the context of their possible roles in modulating amino acid deprivation-induced IGFBP1 hyperphosphorylation in HepG2 cells, a model for fetal hepatocytes204-208.

1.4.1 Mechanistic Target of Rapamycin (mTOR)
1.4.1.1

The two mTOR complexes

mTOR exists in two, ubiquitinously expressed209, functional complexes, mTOR Complex
1 (mTORC1) and mTOR Complex 2 (mTORC2). The two complexes are composed of
both unique and shared proteins. mTOR is the catalytic component common to both
complexes210, which also share DEP domain-contain mTOR-interacting protein
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(DEPTOR), mammalian lethal with Sec13 protein 8 (mLST8), and Tti1–Tel2211-213.
DEPTOR is an endogenous inhibitor of both complexes213 and Ttil-Tel2 regulates
complex formation for both mTORC1 and mTORC2211. mLST8 is critical to mTORC2
function214. Further, each complex is associated with a unique, key functional protein that
responds to external stimuli and accordingly phosphorylates downstream effectors210.
mTORC1 is associated with regulatory-associated protein of mammalian target of
rapamycin (raptor)215 and mTORC2 with rapamycin-insensitive companion of
mammalian target of rapamycin (rictor)214. Raptor has been implicated in amino acid
sensing and sub-cellular localization of mTORC1216. Similarly, rictor phosphorylates
downstream mTORC2 effectors210, recruits substrates214, and confers structural stability
to mTORC2217.
The two complexes are differently regulated with independent and overlapping cellular
functions210. Both complexes are sensitive to inhibition by rapamycin, though mTORC2
requires higher treatment doses and durations173,214. mTORC1 is endogenously inhibited
by tuberous sclerosis 1 and 2 (TSC1-TSC2 complex) in response to a variety of stressstimuli. When activated, mTORC1 phosphorylates and activates eukaryotic translation
initiation factor 4E (4E-BP1) and p70-ribosomal S6 Kinase 1 (p70-S6K), which proceed
to modulate cell growth and proliferation210. mTORC2 phosphorylates downstream
effectors protein kinase C-α (PKCα) and AKT and has been typically implicated in
maintaining the actin cytoskeleton, although recently has also been demonstrated to play
a role in cell proliferation, survival, and morphology217 and in the regulation of lipid
homeostatis218.

1.4.1.2

mTOR as a cellular nutrient sensor

mTOR signaling is sensitive to fluctuations in nutritional status210,219, although the
mechanisms by which mTOR senses nutrient availability have not been completely
elucidated. In particular, mTOR has been proposed to respond to fluctuations in nutrient
status via mTORC1, whereas mTORC2 is proposed to not be directly involved in cellular
energy sensing217. Various factors have been discovered to be necessary for amino acid
sensing by mTOR, suggesting that nutrient sensing by the signaling complex is highly

18

dynamic. Sancak et. al. demonstrated that sufficient amino acid availability is absolutely
necessary for mTOR activity and involves the Rag family of proteins216. Amino acids
promote RagA/B complex association with GTP216. These GTP-bound complexes
subsequently associate with raptor and translocate to the lysosomal membrane where they
interact with Ragulator, an essential component for amino acid sensing by mTORC1209.
Further, Hardie et. al. suggested that cellular energy sensing by mTORC1 occurs via
AMP-dependant kinase (AMPK)220. Adequate nutrient availability is sensed by AMPK,
which subsequently phosphorylates and deactivates TSC1-TSC2 complexes and activates
mTORC1220. Kim et. al. proposed that nutrient deprivation increases the stability of the
mTORC1:raptor complex, sequestering mTORC1 in an inactive complex and inhibiting
its kinase ability221. It is likely that all these components interplay in a dynamic
mechanism to modulate mTOR activity under various nutritional cues.
Amino acid insufficiency leads to decreased phosphorylation of downstream mTOR
effectors222. mTOR activity is especially sensitive to circulating BCAAs. BCAAs
stimulate mTOR activity in multiple cell types223 including murine hepatocytes as
indicated via increased phosphorylation of p70-S6K and 4E-BP1224,225. mTORC1
activation is critically dependant on sufficient amino acid availability, especially on
cellular leucine status226. mTOR signaling is a key component of leucine-stimulated
protein synthesis in catabolic conditions227. Although mTORC2 has been proposed to be
insensitive to amino acid status228, the complete regulation and functions of mTORC2
have not been extensively classified210. Inhibition of mTOR activity by amino acid
deprivation is reversed by the re-introduction of amino acids into the culture media229.
Finally, mTOR nutrient sensing in the placenta has been implicated in FGR onset230-232.

1.4.1.3

mTOR signaling as a potential link between nutrient
deprivation and decreased fetal growth in FGR

Placental mTOR nutrient sensing has been implicated in FGR onset230,231 and is
particularly sensitive to activation by amino acids233. mTOR has been proposed as a key
regulator of the placental expression of amino acid transporters that are critical to EAA
transfer to the fetus32,230,231. Further, mTOR signaling is diminished in placentas from
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maternal nutrient restricted (MNR) rats32, MNR baboons234 and in human FGR
pregnancies230,235. Kavitha et. al. recently demonstrated, in MNR baboons, that mTOR
and IGF-I activity inhibition led to a decrease in placental nutrient transporters and
decreased offspring growth234. The role of mTOR signaling in the fetal compartment in
FGR has been not as well established. Promisingly, our team has recently reported
decreased mTOR activity in baboon hepatocytes from MNR pregnancies173. Further,
Teodoro et. al. reported that BCAA supplementation reversed growth restriction in an
induced murine model of FGR by activating the fetal hepatic mTOR signaling pathway45.
In addition, mTOR signaling is necessary and sufficient for insulin-mediated
inhibition of Igfbp1 gene expression 236-238. Conditioned cell media from mTORC1and mTORC2-silenced trophoblast cells induced IGFBP-1 secretion and
phosphorylation in cultured HepG2 cells 239, and our lab has recently linked
decreased mTOR activity with increased IGFBP-1 protein secretion and
phosphorylation 173. However, whether mTOR is the mechanistic link between amino
acid deprivation and hepatic IGFBP-1 hyperphosphorylation has yet to be
determined.
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Figure 1.2. Model for IGFBP-1 phosphorylation by various components of the mTOR
signaling components.

1.4.2 The Amino Acid Response (AAR)
Amino acid deprivation in mammalian cells activates a collection of intracellular
signaling responses, collectively known as the Amino Acid Response (AAR), which lead
to the induction of a stress-responsive transcriptional program240. The AAR is an
evolutionarily conserved, adaptive cellular response to decreased circulating amino acids
and is part of the Integrated Stress Response (ISR), which is initiated by multiple stresssensing kinases upon distinct environmental stimuli. General control non-derepressible 2
(GCN2) is the specific sensor for the AAR. GCN2 functions exclusively to initiate an
amino acid restriction-specific stress response and its activity is initiated upon reduced
intake of essential amino acids or diminished intracellular synthesis of non-essential
amino acidsvia sensing excess intracellular uncharged tRNAs241. Subsequent

21

GCN2phosphorylation of eukaryotic initiation factor 2 (eIF2a) initiates the AAR, leading
to reduced global protein translationand a concurrent increase in the translation of preexisting stress-responsive mRNAs, most notably Activating Transcription Factor 4
(ATF4). ATF4 is a transcription factor that then proceeds to up-regulate the transcription
of several stress-responsive proteins. Overall protein translation is curtailed in favour of
the up-regulation of a host of stress-responsive genes that serve to restore cellular
homeostatis242.

1.4.2.1

General control non-derepressible 2 (GCN2) is the AAR
nutrient sensor

GCN2 is a serine/threonine kinase and a universally conserved sensor of cellular nutrient
status from yeast (GCN4 homologue)243 to mammalian systems. Among the four ISR
kinases, GCN2 is uniquely sensitive to fluctuations in amino acid availability244. Within
the AAR, GCN2 is the only identified sensor of amino acid depletion245. Deprivation of
even a single amino acid is sufficient to induce GCN2 activity246. Activated GCN2
subsequently initiates stress-responsive downstream signaling pathways via
phosphorylation of eIF2α (Ser51)203,241,247-249.
Structurally, GCN2 contains a catalytic eukaryotic kinase domain that is well-conserved
among all eukaryotic kinases250,251. Of the twelve sub-domains, catalytic subunits IV and
V are the least conserved among eukaryotes250,251. However, there is significant sequence
homology in the V domains between the eIF2α kinases, conferring substrate specificity to
this kinase family252. GCN2 also contains C-terminal ribosome binding/dimerization,
pseudo-kinase(regulatory), histidyl-tRNA (HisRS)-related, and N-terminal RWD
domains that are not structurally conserved among the eIF2α kinases.
GCN2 typically circulates in its inactive form246 in loose association with 80S ribosomes
or actively translating polysomes253. Uncharged tRNAs, which accumulate as a result of
reduced essential amino acid intake or non-essential amino acid synthesis, preferentially
bind the HisRS domain over charged tRNAs245. tRNA binding leads to GCN2
dimerization254 and subsequent autophosphorylation at Thr898255, causing kinase
activation. tRNA binding is facilitated by the binding of a GCN1/GCN20 protein
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complex to the RWD domain256,257 and by certain C-terminal lysine residues on GCN2256,
conferring additional sensitivity to the nutrient sensor. There are two reports of GCN2
binding to viral RNA258,259, however, eIF2α is the only currently established target for
GCN2 phosphorylation in mammalian systems.
The role of GCN2 in amino acid sensing is widely acknowledged. GCN2+/GCN2+ mice
displayed decreased hepatic and adipose mass in response to leucine starvation, whereas
GCN2-/GCN2- mice livers were not affected in size but rather displayed pronounced
steatosis260. GCN2-/GCN2- mice do not avoid essential amino acid-deprived diets unlike
their wild-type counterparts261,262 and have decreased rates of survival263. GCN2 is also
sensitive to glucose deficiency264,265.
GCN2 phosphorylation of eIF2α occurs in a MEK/ERK dependant manner266 (discussed
further in section 1.4.2.3), which subsequently proceeds to initiate a stress-responsive
transcriptional program via the increased translation of pre-existing ATF4 mRNAs and
concurrent decrease in overall protein translation241. Increased GCN2 and eIF2α (pSer51)
phosphorylation and ATF4 expression are therefore indicators of AAR pathway
activation.

1.4.2.2

AAR propagation via eukaryotic initiation factor 2 alpha
(eIF2α) phosphorylation and ATF4 expression

eIF2 is a heterotrimer of α, β, and γ subunits248,257 and participates in mRNA translation
by mediating Met-tRNA binding to the ribosome227,267. The process of translation
initiation by eIF2 is GTP dependant 268,269. eIF2γ is the main docking site for GTP/GDP,
and eIF2β catalyzes eIF2-GDP conversion to eIF2-GTP. eIF2α is the enzyme’s
regulatory subunit268,269. Phosphorylation of eiF2α at Ser51 increases its affinity for
eIF2β251, thereby sequestering eIF2β-GDP in its inactive complex. Consequently, eIF2β
is unable to catalyze the nucleotide exchange, reducing the functional capacity of the
translation factor270.
eiF2α is phosphorylated by four distinct stress-responsive kinases, rendering it the
convergence point for the ISR242,271. eIF2α is exclusively phosphorylated by the four ISR
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kinases in vivo, and sequence determinants remote from Ser51 have been proposed to
confer this specificity268. The phospho-acceptor site (Ser51) on the alpha subunit is
buried within a hydrophobic pocket preventing its phosphorylation by other in vivo
kinases268,269. Kinase binding to eIF2α induces a conformational change that projects
Ser51 into the active site, allowing its phosphorylation268,269.
In mammalian cells, in addition to GCN2, eIF2α is also phosphorylated by the three other
ISR kinases depending on the particular stressor: heme-regulated inhibitor kinase (HRI),
double-stranded RNA-activated protein kinase (PKR), and PKR-like endoplasmic
reticulum (ER) kinase (PERK). The transcriptional program elicited by eIF2α
phosphorylation reduces global translation in favor of up-regulating gene products
involved in cellular stress-management244. In a study by Dang et. al., 2.5% of total
murine hepatic mRNA was down-regulated by eIF2α phosphorylation272.
PERK is a component of the Unfolded Protein Response (UPR) that is activated under
endoplasmic reticular (ER) stress242,271 and has been most commonly investigated
alongside GCN2 in regards to the transcriptional program that is elicited upon cellular
stress. ATF4 induction, characteristic of eIF2α phosphorylation, which is intitiated by
PERK elicits an overlapping transcriptional program with that of up-regulated ATF4 by
GCN2 activation, suggesting that ATF4 is a critical signaling convergence point from
cellular stress derived from amino acid insufficiency and from oxidative stress273. A
comprehensive analysis of the gene profiles elicited by GCN2 and PERK in murine
hepatocytes indicates that although some overlap exists in the programs elicited by GCN2
and PERK, each cellular stressor has a vastly distinct overall affect on the hepatic
transcriptome272. The stress response elicited by AAR activation is therefore likely
affected by a multitude of factors downstream of GCN2 and is not specific to ATF4.
Specific attenuation of the AAR is therefore best accomplished via direct manipulation of
GCN2.
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AAR

HRI
PKR

Other ISR
kinases

PERK

Stress-responsive transcriptional program
Figure 1.3. Overview of signaling components of the Amino Acid Response (AAR) as a
component of the Integrated Stress Response (ISR).

1.4.2.3

Involvement of MAPKs in the AAR

The Mitogen-Activated Protein Kinase (MAPK) family of serine/threonine kinases is
widely conserved among eukaryotic species, and encompasses a three-tier system of
kinases. MAPKs are phosphorylated upstream by MAPK kinases (MKKs), which in turn
are phosphorylated by MEK Kinases (MKKKs)274. MKKs are dual specificity kinases
that phosphorylate Thr-X-Tyr motifs on their respective MAPKswhich in turn
phosphorylate their own downstream targets, many of which are transcription factors275.
There are four subfamilies of the MAPK signaling cascades in mammalian cells, each of
which is involved in unique and overlapping intracellular functions274. Each subfamily
contains several MAPKs, MEKs, and MKKs, serving as multiple integration points for
various intracellular signals. One signaling arm (MEK1/2/ERK1/2) in particular is critically
involved in cell growth and proliferation; the MAPKs in this cascade are known as ERK1
and ERK2, and this signaling arm will herein be referred to as MEK/ERK. An overview
of the various components of the MEK/ERK signaling cascade is illustrated in Figure 1.3.
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Various Growth Factors

MKKK

Raf1, A-Raf,B-Raf, Mos,
MEKK1, MEKK2, MEKK3, Tpl2

MKK

MEK1, MEK2

MAPK

ERK1, ERK2

Cell growth and differentiation
Figure 1.4. Schematic representation of the mitogenic (MEK/ERK) pathway including
all potential MKKKS, MKKs, and MAPKs
The literature purports that MEK/ERK signaling is necessary for AAR propagation245,266.
Inhibiting MEK/ERK signaling is therefore a strategy for attenuating the AAR. However,
the role of MEK/ERK in cell growth and proliferation274 suggests it may independently
modulate IGFBP-1 secretion and phosphorylation. Inhibition of MEK/ERK signaling has
been shown to decrease IGFBP-1 secretion in the human endometrium276 and secretion of
both IGF-I and IGFBP-1 in rat hepatocytes 277,278. MEK/ERK signaling has also been
implicated downstream of IGFBP-1 in modulating mitogenesis in the liver279. Various
studiesreport differential involvements of MEK/ERK signaling in IGFBP-1 regulation280282

. However, its explicit role in the secretion and phosphorylation of IGFBP-1 in nutrient

restriction, and whether these effects occur via the AAR, are unknown.

1.4.2.4

Potential role of the AAR in IGFBP-1 regulation under
nutrient restriction in FGR

Decreased transfer of EAAs from the mother to fetus is observed in FGR22,283,284, and the
extent to which fetal amino acid transfer is restricted is correlated with FGR severity283.
An important study by Strakovsy et. al. demonstrated that the AAR is activated in
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placentas of rats fed nutrient-restricted diets during gestation, which also led to stunted
growth of neonates285. More recently, increased eIF2α phosphorylation has been detected
in placentas from human FGR pregnancies235. Considering that the AAR is an adaptive
cellular response to restricted amino acids, and that FGR results from a maladaptive
physiological response to decreased nutrient availability, it is extremely likely the AAR is
implicated in FGR onset.
The amino acid-specific, and AAR-mediated, regulation of IGFBP-1 has been
demonstrated at the transcriptional and translational levels. IGFBP-1 expression is
induced downstream of ATF4 in murine hepatocytes286. Further, in vitro 287and in vivo288
studies support this observation by demonstrating that dietary amino acid restriction in
rats leads to induced hepatic IGFBP-1 mRNA expression288. Conversely, murine IGF-I
gene expression is down-regulated by amino acid restriction289. Amino acid restrictioninduced hepatic IGFBP-1 mRNA is dependent on specific regions in the IGFBP-1
promoter (IRE, GRE)290, subsequently named the Amino Acid Response Unit
(AARU)291. Increased IGFBP-1 species in response to amino acid deprivation is
accomplished in part by mRNA stabilization287 in addition to increased transcription.
Upstream stimulatory factors 1 and 2 (USF-1, USF-2) have been identified as potential
transcription factors in protein restriction-induced IGFBP-1 transcription 291. USF-1 and 2 are ubiquitously expressed and up-regulated in protein restricted conditions291,
suggesting that regulation of total IGFBP-1 output may be under the control of the AAR
via stress-induced up-regulation of various downstream transcriptional factors.
Interestingly, Averous et. al. demonstrated that primary hepatocytes derived from mice
deficient for GCN2 were still able to induce IGFBP-1 transcription under leucine
restriction287. Together, the literature suggests that the AAR is partly involved in
modulatingIGFBP-1 expression; however, the involvement of the AAR in the translation
and post-translational regulation of IGFBP-1 has not been classified.
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1.5

Kinases involved in the regulation of IGFBP-1

phosphorylation
Phosphorylation of IGFBP-173, IGFBP-3292 and IGFBP-5184 has been unequivocally
demonstrated, while other IGFBPs display potential phosphorylation sites140. IGFBP-1 is
likely phosphorylated by intracellular kinase(s) prior to its secretion293. Consensus
sequence analysis and in vitro studies indicate that IGFBP-1 is a potential substrate for
protein kinase CK2, protein kinase C (PKC) and protein kinase A (PKA)140,168,188,293.
Here, we review these three potential kinases for their potential involvement in IGFBP-1
phosphorylation under leucine deprivation.

1.5.1 Protein Kinase CK2
1.5.1.1

Structure and Function

CK2 is a constitutively active, ubiquitous serine/threonine kinase with over 300 potential
targets294,295 including IGFBP-1293. Ubiquitinously expressed in mammalian cells296 ,
CK2 exists in a tetrametric form with two identical regulatory (β) subunits297,298 and two
catalytic subunits (α and/or α')298-302. CK2 characteristically phosphorylates Ser or Thr
residues located in close proximity to acidic amino acids140,297,303 (consensus sequence: SX-X-D/E) (Table 1.1). However, this minimal consensus sequence has been shown to be
neither necessary304 nor sufficient305 for phosphorylation by CK2, suggesting that other
structural determinants are involved in potentiating phosphorylation by CK2.
Differing only in their C-terminal domains, CK2a and CK2a' catalytic domains are 90%
identical306 and exhibit highly similar in vitro enzymatic properties307. CK2β is highly
conserved among species with identical sequence homology in birds and
mammals296,308,309. CK2 has been found to be localized in the cytoplasm as well as
multiple intracellular organelles310, functioning as both an endokinase310 and
ecktokinase310,311. CK2 subunits each target different substrates312,313 and are individually
implicated in robust regulatory cellular functions296. CK2 activity is responsive to various
stress stimuli in mammalian cells314-318.
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1.5.1.2

CK2 phosphorylation of IGFBP-1

CK2 phosphorylates IGFBP-1 in HepG2293 and endometrial stromal cells188. IGFBP-1
phosphorylation sites (Ser101, Ser119, Ser169) exist in proximity to acidic amino acids,
characteristic of the CK2 consensus recognition motif 319,140(Table 1.1). However,
whether or not IGFBP-1 is a true CK2 substrate has not been conclusively demonstrated.
Previously in our lab, inhibition of CK2 activity via combined siRNA silencing of CK2α,
CK2α’ and CK2β or selective CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB)
decreased IGFBP-1 phosphorylation in HepG2 cells173. Additionally, our team has shown
that CK2 activity and IGFBP-1 phosphorylation are concomitantly elevated in growthrestricted fetal baboon hepatocytes from nutrient-restricted mothers173. Previous work
from our lab also showed that CK2 is a key regulator of IGFBP-1 phosphorylation
(pSer101, pSer119, pSer169) downstream of mechanistic target of rapamycin (mTOR)
signaling173. Whether CK2 mediates IGFBP-1 phosphorylation in amino acid deprivation
remains to be established.

1.5.2 Protein Kinase C (PKC)
1.5.2.1

Structural and functional basis for inhibition

PKC is another indiscriminate protein kinase and is activated intracellularly by second
messenger diacylgycerol320. The role of PKC in IGFBP-1 phosphorylation has not been
established. Although PKC is a potential kinase for IGFBP-1 phosphorylation140, based
on the PKC consensus sequencewhich requires surrounding basic residues to the
phospho-acceptor site140, Ser101, Ser119 and Ser169 on IGFBP-1 are not likely sites for
direct phosphorylation by PKC. However, PKC has been shown to be pivotal in the
regulation of IGF-I bioactivity through uncharacterized mechanisms321-327.
PKC is widely expressed in mammalian tissues. PKC consists of a regulatory N-domain
and catalytic C-domain, and 4 conserved and 5 variable regions in its primary structure.
11 PKC isoforms (α, βI, βII , γ, δ, ε, θ , η, ζ , √, λ) have been identified with minor
structural and functional differences328. PKC isoforms α, βI, βII and γ are considered
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conventional isotypes (cPKCs) and share conserved (C1 and C2) modules in their
regulatory domains328. Novel PKCs (nPKCs) consist of the δ, ε, θ and η isotypes and lack
the C2 subunit, whereas atypical PKCs (aPKCs - ζ , √ and λ) lack both C2 and integral
structural components of C1 rendering them insensitive to activation by diacylglycerols
(DAGs) and phorbol esters328. The isoforms are variably regulated by intra- and extracellular stimuli329 and the expression of certain isoforms is restricted to specific cell
types: γ to the central nervous system, θ to the skeletal muscle and hematopoietic cells,
and β to the pancreatic, adrenal and neuronal tissue329. There is also evidence for
differential sub-cellular localization of the various PKC isoforms329. The PKC isoform
profile of HepG2 cells has not been exclusively classified, although certain PKC isoforms
have been specifically implicated in various stress-related responses in HepG2 cells330,331.
PKC has been implicated in multiple diseases phenotypes, and the specific roles of
individual isoforms are emerging in the literature330.The development of pharmacological
tools to elucidate the stimuli- and cell-specific roles of the various PKC isoforms is a
current topic of investigation328.
Staurosporine is the most widely used chemical inhibitor against PKC. Although its
effects are potent, it has demonstrated cross-reactivity with other kinases including
protein kinase A (PKA)332. On the other hand, a less potent derivative of staurosporine,
Bisindolylmaleimide (BIS), is a very specific PKC inhibitor for all PKC isoforms332.

1.5.2.2

PKC as a nutrient-sensitive kinase and its possible role in
FGR

PKC activity is sensitive to fluctuations in nutrient availability. PKC integrates signals
downstream of mTOR in an amino acid-sensing pathway and certain PKC subunits
(α,δ,ε) are regulated by mTOR in amino acid-dependant manner. PKC functions
downstream of mTOR to stimulate mitogenic protein synthesis 333 including leucineinduced DNA synthesis as assessed in cultured chicken hepatocytes 334. Nishitani et.
al. demonstrated that leucine-mediated glucose uptake occurs via PKC signaling 335.
However, leucine supplementation in rats stimulates hepatic PKC activity as well as
redistribution of the kinase from the hepatocellular membrane to the cytosol through
mTOR-independent mechanisms 336, suggesting that PKC is also independently
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sensitive to nutrient supply. Further, PKC signaling is abrogated in certain nutritional
disorders. For example, hepatic PKCα signaling participates in nutrient transport and
its function is implicated in obesity and diabetes mellitus II 337. PKC activity was
attenuated in the pancreas338 and skeletal muscle339 of rats subjected to reduced protein
intake during gestation.
Finally, there is some evidence for the involvement of PKC in FGR onset. One study
demonstrates an altered expression profile of the various PKC isoforms in placentas from
murine FGR pregnancies during the third trimester340. Artificially-induced hypoxia
potentiated PKCα activity in human umbilical venous endothelial cells from normal
pregnancies to comparable levels seen in the same cells derived from FGR pregnancies341
and hepatic PKCζ expression is increased in FGR rats342. Together, these studies
implicate a possible role for altered PKC signaling in FGR onset.

1.5.2.3

Interactions between PKCand the IGF/IGFBP signaling
axis

Various isoforms of PKC have been implicated in modulating the cellular actions of IGFI in a variety of tissues. While PKCα up-regulates IGF-I bioactivity in microtubes321,
PKCζ modulates IGF-I-stimulated macrophage differentiation322 and along with PKCβ,
PKCη, and PKCε, plays an essential role in IGF-I-mediated migration of vascular smooth
muscle cells, DNA synthesis and gene expression323. PKCζ signaling modulates IGF-I
bioactivity in vascular smooth muscle cells324 and PKCθ has been shown to be critical in
IGF-1R mediated oncogenic cell proliferation325. PKCζ modulates the effect of growthinducing hormones (e.g. insulin) on downstream mitogenic protein synthesis and cell
cycle progression327. Inhibition of pan-PKC with BIS inhibited both IGF-I-stimulated
early cell differentiation and later cell proliferation in messenchymal cells326. Induction of
pan-PKC activity stimulates HepG2 cell proliferation343.
There is evidence for PKC regulation of the IGFBPs. Multiple PKC isoforms have been
implicated in regulating IGFBP-2 and IGFBP-3 secretion by thyroid cells344-346. PKCα
phosphorylates IGFBP-3, inducing its degradation347. Further, pan-PKC inhibition
induces IGFBP-5 synthesis348 and secretion349,350 and IGFBP-4 secretion349 in multiple
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cell types. There is also some support for the role of PKC in the regulation of IGFBP1output. For example, a study by Kachra et. al. in rat hepatocytes revealed that glucagon
inhibited IGFBP-1 mRNA expression via activation of PKC signaling351. Further, PKC
plays a role in both the up- and down- regulation of IGFBP-1 secretion in vitro at the
protein level, depending on the parameters of the exposure to the inhibitors352,353.
The role of PKC in post-translational regulation of IGFBP-1 has not been classified.
Given the nutritional sensitivity of PKC, its role in the regulation of IGF-I bioactivity and
IGFBP-1 expression, and its dynamic interactions with members of the IGFBP family of
proteins, we considered it a valuable kinase to assess for its role in the elusive signal
transduction pathway modulating IGFBP-1 phosphorylation under leucine deprivation.

1.5.3 Protein Kinase A (PKA)
1.5.3.1

Structural and functional basis for inhibition

PKA is a multifunctional, ubiquitously expressed, intracellular kinase with a wide variety
of protein targets320,354, and is activated by secondary messenger cyclic AMP
(cAMP)320,354. PKA is a heterotetrameric kinase, with two catalytic subunits containing
dimerization and regulatory subunit-binding domains as well as binding sites for the
kinase’s substrate and for ATP, the kinase’s phosphate source. cAMP binding to the
homodimeric regulatory subunits causes its dissociation and consequent activation of the
catalytic subunits. PKI (5-24) is a highly potent, competitive inhibitor of PKA. PKA
residues Tyr235 and Phe239 on the regulatory subunits structurally integrate with Phe10
of PKI, preventing substrate (cAMP) binding and subsequent activation of PKA355.

1.5.3.2

PKA as a nutrient-sensitive kinase

Hepatic PKA activity is sensitive to fluctuations in nutrient availability356-359. PKA
signaling is potently decreased in murine livers after offspringwere fed low-protein
diets357,358. Further, murine pancreatic PKA expression is reduced by nutrient
restriction360. Decidualization of human endometrial stromal cells during human
pregnancy occurs in a PKA-dependant mechanism361 and the increased IGFBP-1
production characteristic of this process is also dependant on PKA signaling361-363.
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Finally, altered PKA signaling has been implicated in fetal brain development in
FGR364,365.

1.5.3.3

Interactions between PKA and the IGF/IGFBP signaling
axis

PKA has been implicated in modulating systemic IGF-I mitogenic actions in multiple cell
types366-368. For example, PKA regulates IGF-I-stimulated osteoclast-like cell
formation369, and PKA inhibition prevents IGF-I stimulated early chondrocyte cell
proliferation and differentiation326. PKA kinase activity stimulates the IGF-I promoter370.
The majority of studies linking PKA and the IGFBPs focus on PKA-regulation of IGFBP
expression and synthesis in multiple cell types. PKA activation prevents chondrocytic
IGFBP-3 and IGFBP-4 expression and secretion371 as well as antagonizes IGFBP-4 and
IGFBP-5 secretion in the murine ovaries348. Conversely, PKA stimulation induces
IGFBP-5 expression350. Importantly, induction of PKA activity stimulates IGFBP-1
promoter activity372, mRNA372 expression and protein372,373levels in HepG2 cells. PKA
activation modulates glucagon-stimulated IGFBP-1 expression in rat hepatocytes351.
Conversely, PKA inhibition attenuates cAMP-stimulated IGFBP-1 synthesis.
Promisingly, one study188 links PKA to IGFBP-1 phosphorylation in endometrial stromal
cells.
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Table 1.1. Surrounding peptide sequence of the three IGFBP-1 phosphosites and
consensus sites for CK2, PKC and PKA
Peptide

Surrounding peptide sequencea

IGFBP-1(E97-S101-L110)

ESPEpSTEITEEELL

IGFBP-1(D111-S119-E121)

DNFHLMAPpSEE

IGFBP-1(A165-S169-K175)

A QETpSGEEISK

Kinase

Consensus siteb

CK2

S/T-X-X-D/E

PKC

S/T-X-R/K

PKA

R/K-R/K-X-S/T

a

Abu Shehab M et. al. Site specific phosphorylation of insulin-like growth factor binding protein-1 (IGFBP-1) for
evaluating clinical relevancy in fetal growth restriction. J Proteome Res. 2009;8(11):5325-5335.
b Coverley JA, Baxter RC. Phosphorylation of insulin-like growth factor binding proteins. Mol Cell Endocrinol.
1997;128(1-2):1-5

1.5.4 IGFBP-1 de-phosphorylation
Westwood et. al. proposed that IGFBP-1 dephosphorylation is another regulatory
mechanism by which cells can stimulate IGF-I bioactivity by releasing the growth factor
from sequestration151,166. Alkaline phosphatase (ALP) was recently identified as the
phosphatase which de-phosphorylates IGFBP-1 in vitro167 and in vivo374to decrease its
propensity for IGF-I binding167. During pregnancy, placental ALP de-phosphorylates
IGFBP-1 in order to increase IGF-I bioavailability374. Therefore, dephosphorylation of
IGFBP-1 may be an additional mechanism by which cells modulate IGF-I bioavailability
in FGR.
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1.6

Experimental models

1.6.1 Leucine deprivation as a model for nutrient restriction
BCAAs are the key stimulators of global protein synthesis 227. Supplementation of
murine hepatocytes with EAAs, but particularly the BCAAs, maximally induces
plasma protein synthesis, as indicated by induction of albumin and tranferrin
secretion375. BCAA repletion alone is sufficient to maximally induce protein
synthesis in skeletal muscle 376. Leucine, along with isoleucine and valine, is a BCAA
and one of the nine EAAs in humans. Leucine accounts for more than 20% of human
dietary protein 223. Administration of BCAAs, but specifically leucine, has mitogenic
effects in the liver, such as the synthesis of hepatocyte growth factor, as well as in
hepatocellular regeneration377. In addition to its structural role in protein synthesis,
leucine has one of the most potent roles in intracellular signaling compared to other
essential amino acids223.
Studies of placental nutrient transfer in FGR have focused on trans-placental leucine
transport, which is potently and consistently decreased in FGR22,46,47,378. Assessment of
venous umbilical samples indicates that leucine and phenylalanine most rapidly cross
the placenta from the mother to the fetus 47, and that leucine transport is particular
heightened after 20 weeks gestation in human pregnancies 48.Oral administration of
leucine augments protein synthesis in multiple tissue and cell types 379,380, however,
does not affect global protein synthesis in the liver 379,381. Rather, hepatic leucine
administration induces the expression of specific mRNAs and significantly activates
mTOR signaling263,381.
There is strong evidence in the literature suggesting that leucine is unique in its
ability to stimulate protein synthesis to the maximal level comparable to a mixture of
all EAAs227,376in vivo. In previous in vitro studies in our lab, leucine deprivation
reliably triggered IGFBP-1 hyperphosphorylation at Ser101, Ser119 and Ser169 in
HepG2 cells 190.
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1.6.2 HepG2 cells as a model for fetal hepatocytes
As described previously (Section 1.3.2), fetal liver is the primary source of fetal
circulating IGFBP-1. In vitro, HepG2 cells are an ideal, widely-used model for human
fetal hepatocytes 204-208. They express a transcriptome and secretome206,382,383 most
similar to human fetal hepatocytes. HepG2 cells induce IGFBP-1 mRNA expression
when limited for leucine without affecting the expression of IGF-I198. Previous work in
our lab demonstrated that, in a HepG2 cell culture model, leucine deprivation-induced
phosphorylation of IGFBP-1 led to up a 21-fold increase in affinity for IGF-I in
vitro190. Further, our lab has recently demonstrated that changes in IGFBP-1 secretion
and phosphorylation in HepG2 cells are reflected in primary baboon hepatocytes173,
which have served a successful, physiologically relevant model in the study of regulation
of IGFBP-1 phosphorylation in FGR173,384. Therefore, it is justified to use HepG2 cells to
study the mechanisms underlying leucine deprivation-induced fetal hepatic IGFBP-1
phosphorylation.

1.7

Scope of Thesis

The fetal response to decreased nutrient (amino acid) supply likely involves multiple
signaling pathways in an effort to optimize fetal health. A maladaptive molecular
response to amino acid restriction is detrimental to fetal outcomes53. The signaling
mechanisms linking amino acid deficiency to decreased cell growth and proliferation in
FGR have not been elucidated. As described previously, the bioavailability of IGF-I is a
key determinant of its ability to stimulate fetal cell growth and proliferation; IGFBP-1
phosphorylation (Ser101, Ser119 and Ser169) is an indicator of decreased IGF-I
bioavailability and is increased in FGR. The mechanisms regulating IGFBP-1 secretion
and phosphorylation under amino acid deprivation, which is a keycontributing factorto
FGR onset, remain to beestablished. The overall objective of this study is to shed light on
the molecular mechanisms by which fetal growth is regulated under amino acid
deprivation by studying the signaling pathways modulating leucine deprivation-induced
IGFBP-1 phosphorylation in vitro. The central hypothesis is that leucine deprivationinduced IGFBP-1 phosphorylation is modulated via down-regulation of the mTOR
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signaling cascade and up-regulation of the AAR pathway. Further, we predict that
IGFBP-1 phosphorylation under leucine restriction is modulated by multiple protein
kinases (CK2, PKC, PKA). The specific aims encompassed in this thesis are three-fold:
Aim 1: Determine the role of mTOR signaling in mediating leucine deprivation-induced
IGFBP-1 secretion and phosphorylation (pSer101, pSer119 and pSer169) (Chapter 2).
Aim 2: Establish whether the AAR is involved in modulating leucine deprivationinduced IGFBP-1 secretion and phosphorylation (pSer101, pSer119 and pSer169) and
whether this occurs in a MEK/ERK-dependant manner (Chapter 2).
Aim 3:Surveypotential kinases that may be involved in regulating IGFBP-1
phosphorylation (pSer101, pSer119 and pSer169) under leucine deprivation (Chapter 3).

Amino Acid Deprivation
mTOR

AAR
CK2, PKC, PKA

IGFBP-1

pIGFBP-1
Figure 1.5. Proposed model for total and phospho-IGFBP-1 regulation by mTOR, AAR,
and the kinases CK2, PKC and PKA under fetal amino acid deprivation
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In Chapters 2 and 3, we analyze changes in IGFBP-1 secretion and phosphorylation in
HepG2 cell media after treatments which have manipulated various molecular
components of the mTOR and AAR signaling pathways or protein kinases CK2, PKC
and PKA in both regular (leucine plus) or leucine minus conditions. Changes in IGFBP-1
secretion and phosphorylation are linked to concomitant changes in the activity of
downstream pathway components. Identifying signaling pathways involved in leucine
deprivation-mediated IGFBP-1 phosphorylation in vitro will provide the foundation for
future in vivo studies aimed at contributing insight into the pathophysiology of FGR.
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Total and phosphorylated IGFBP-1 in leucine deprivation:
roles for the mTOR and AAR signal transduction pathways
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2.1

Introduction

Fetal Growth Restriction (FGR) arises from a heterogeneous group of factors and
although its etiology is multi-factorial, FGR is primarily a result of placental
insufficiency, i.e. the inability of the placenta to effectively deliver nutrients and oxygen
to the fetus1,2. FGR infants fail to achieve their full growth potential after suffering
nutritional deprivation3 and are at an increased risk for perinatal mortality4. FGR affects
~5 to 7% of all pregnancies5. FGR babies born under the 10th percentile for estimated
birth weight are predisposed to greater risks of childhood and adult metabolic,
cardiovascular, and neurological complications4,6,7. The mechanisms by which the fetus
signals nutrient deficiency to attenuating fetal growth are not well understood.
Insulin-like growth factor I (IGF-I), synthesized mainly by the fetal liver, is a key
regulator of fetal growth. Fetal serum IGF-I levels are significantly reduced in the
growth-restricted fetuses8. IGF binding protein-1 (IGFBP-1) primarily secreted by the
fetal liver9 is the key fetal circulating IGFBP during gestation10. Elevated fetal circulating
IGFBP-1 and decreased IGF-I levels are strongly correlated with FGR onset11-13. IGFBP1 functions by binding IGF-I and sequestering it from its receptor, IGF-1R, consequently
preventing it from transducing mitogenic signals14-16. Phosphorylation of IGFBP-1
increases the binding affinity of IGFBP-1 for IGF-I17 and sequesters IGF-I thereby
resulting in its decreased bioavailability16,18-20.
Human FGR fetuses often have decreased fetal circulating levels of essential amino
acids, such as leucine21-24. In our laboratory, we have previously demonstrated that
leucine deprivation triggered hyperphosphorylation of IGFBP-1 in HepG2 cells at
discrete sites, which markedly increased the affinity of IGFBP-1 for IGF-I, and inhibited
IGF-I-dependent cell growth25. Although modest increases in IGFBP-1 phosphorylation
were found in HepG2 cells cultured under lower leucine concentrations (70 and 140 μM
leucine), leucine deprivation (0 µM leucine) distinctly increased IGFBP-1
phosphorylation compared to HepG2 cells cultured with leucine (450 µM leucine)25.
Furthermore, we have recently demonstrated that IGFBP-1 phosphorylation was
increased at three different sites (Ser101, Ser119, and Ser169) in human umbilical cord
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plasma from FGR pregnancies and in liver from baboon FGR fetuses26. These data
indicate that increased phosphorylation of IGFBP-1 at specific sites plays an important
role in FGR pathogenesis.
FGR is characterized by decreased amino acid availability2,27, which activates the Amino
Acid Response (AAR)28 and inhibits mechanistic target of rapamycin (mTOR)
signaling29,30. The AAR signaling pathway is highly responsive to changes in amino acid
availability28. Amino acids, oxygen and growth factor signaling activate mTOR
signaling30-33. mTOR integrates nutrient and mitogenic signals to regulate cell growth and
cell division34. mTOR exists in two complexes, mTOR Complex 1 (mTORC1) and 2,
with the protein raptor associated to mTORC1 and rictor associated to mTORC235,36.
Activated mTORC1 phosphorylates 4E-BP1 and p70-S6K and promotes protein
translation34,37. mTORC2 phosphorylates Akt and PKCα and regulates cell metabolism
and survival36,37. Oxygen, growth factor and amino acids, particularly leucine and
arginine, activate mTORC1 signaling32,38-41. mTORC1, in particular, is inhibited by the
binding of rapamycin although longer treatments and higher doses of rapamycin have
also been shown to inhibit mTORC226,37.
We have previously shown using HepG2 cells and baboon fetal hepatocytes in vitrothat
inhibition of mTOR signaling resulted in increased IGFBP-1 phosphorylation at the three
specific sites26. In addition using a baboon model of FGR in the same study we also
identified that increased site-specific IGFBP-1 phosphorylation in FGR is linked with an
inhibition of the mTOR and stimulation of protein kinase CK2. However, the
mechanisms underlying IGFBP-1 hyperphosphorylation specifically in conditions of
amino acid deprivation remain to be established.
The AAR pathway is activated under conditions of cellular nutrient stress28,42-47. General
control non-derepressible 2 (GCN2) is the key sensor of cellular nutrient status, which is
activated upon sensing excess uncharged cytoplasmic tRNAs45,46. Leucine deprivation
activates and phosphorylates GCN2 at pThr898 which subsequently phosphorylates
eukaryotic initiation factor 2 (eiF2) at pSer51 of the alpha subunit (eiF2α)47.
Phosphorylated eiF2α (pSer51), which is increased in abundance in FGR48, proceeds to
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inhibit eIF2B activity and therefore overall global protein synthesis while concurrently
promoting the translation of certain stress-responsive mRNAs, including activating
transcription factor 4 (ATF4)45,47. ATF4 is a critical stress-responsive transcription factor,
which, when synthesized, promotes the transcription of several growth-arresting genes49.
eiF2α (pSer51) phosphorylation and total ATF4 expression levels are therefore functional
readouts of AAR activity. The role of the AAR signal transduction pathway in regulating
IGFBP-1 phosphorylation has, to our knowledge, not previously been investigated.
In this study, we hypothesized that inhibition of mTOR signaling and AAR activation
increase IGFBP-1 secretion and phosphorylation at specific sites in response to amino
acid deprivation. We used HepG2 cells as a model for human fetal hepatocytes50-54 to
investigate the mechanisms linking mTOR and AAR signaling with IGFBP-1
phosphorylation under leucine deprivation. We studied the secretion and phosphorylation
of IGFBP-1 in HepG2 cells in response to mTOR inhibition (rapamycin) or AAR
inhibition (U0126). Alternatively, cells were transfected with siRNA targeting
raptor+rictor or DEP domain-containing mTOR-interacting protein (DEPTOR) (to inhibit
or activate mTORC1 and C2, respectively)37, and ERK1/2 and/or GCN2 (to inhibit ERKmediated AAR)45,55 in cells cultured with or without leucine. Finally, we verified that
changes in IGFBP-1 phosphorylation under leucine deprivation altered IGF-I bioactivity
by employing our previously established IGF-1R autophosphorylation assay26,56 which
supported the functional significance of our findings.

2.2

Methods

2.2.1 Cell culture
Human hepatocellular carcinoma cells (HepG2), purchased from ATCC (Mananassas,
VA), were cultured in Dulbecco’s modified Eagle medium with nutrient mixture F-12
(DMEM/F-12) supplemented with 10% fetal bovine serum (FBS) (Invitrogen Corp.,
Carlsbad, CA) at 37°C in 20% O2 and 5% CO2 as we described previously25,26.
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2.2.2 Leucine deprivation
HepG2 cells were treated in specialized DMEM/F12 selectively deprived and restored of
specific amino acids and were incubated in the specialized media either deprived of (0
μM) or supplemented with (450 µM) leucine as we described in our previous study25.
Cells were further incubated in leucine plus or leucine deprived media during rapamycin
(100 nM), U0126 (10 μM), or TBB (1 μM) treatments or following transfection with
siRNA. Cell media and cell lysate were collected following 24 hour (chemical
treatments) or 72 hour (siRNA treatments) exposure to the specialized media.

2.2.3 Inhibitor treatments
HepG2 cells were plated in 12-well culture dishes until cultures reached 75% confluence
then starved for 6 hours in 2% FBS (DMEM/F12) prior to treatments with chemical
inhibitors. Based on previous dose-dependency data, HepG2 cells were treated post-6
hour starvation for 24 hours using 100 nM rapamycin, 1 μM TBB as we reported
previously26 or treated with 10 μM U0126 after assessment via dose-dependency
experiments. Following treatments, cell media and cell lysate were prepared as we
described26 and stored at -80°C.

2.2.4 RNA interference silencing
HepG2 cells were plated at 65% confluence in 12-well culture plates. Silencing using
siRNA against raptor+rictor, DEPTOR, GCN2 (Sigma-Aldrich, St Louis, MO, USA) or
ERK (Cell Signaling Technologies, Beverly, MA, USA) in HepG2 cells was achieved
using transfection with 100 nM siRNA and 5 μL Dharmafect transfection reagent 4
(Thermo Scientific, Rockford, IL, USA) in regular, serum free DMEM/F12. To
simultaneously ensure maximal silencing and maximize cell survival, the transfected cell
media was replaced after 24 hours with specialized leucine plus or leucine deprived
media and studied after 72 hours (96 hours following transfection). Western immunoblot
analysis was used to determine the efficiency of target silencing.
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2.2.5 Cell viability assay
We tested the effect of leucine deprivation, TBB and U0126 treatments on cell viability
using the Trypan Blue exclusion assay to ensure these treatments did not sacrifice cell
viability. Following leucine deprivation and U0126 treatments, cells were trypsinized and
re-suspended in 10% FBS media. Cell suspensions were diluted 1:1 with 0.4% Trypan
blue and counted with the Countess Automated Cell Counter (Life Technologies,
Carlsbad, CA). A measure of live/total cells was used as an indicator of cell survival.

2.2.6 SDS-PAGE and Western Blotting
Equal amounts of cell lysate protein (35-50 μg) were separated by SDS-PAGE to
determine total expression and phosphorylation of p70-S6K (Thr389), Akt (Ser473),
ERK (Thr202/pTyr204), eiF2α (Ser51), GCN2 (Thr898), and IGF-1Rβ (Tyr1135), as
well as total expression levels of siRNA target proteins, ATF4 and β-actin (Appendix A;
Supplementary Table 1). IGFBP-1 secretion and phosphorylation (Ser101, Ser119 and
Ser169) by HepG2 cells were determined using equal volume of cell media (30-40 μL).
Nitrocellulose membranes from immunoblot analyses were shaken with 5% skim milk or
5% BSA diluted in Tris-buffered saline (TBS) plus 0.1 % Tween-20 and blocked for 1
hour. All primary antibodies were obtained from Cell Signaling Technologies (Beverly,
MA, USA) with the exception of monoclonal antihuman IGFBP-1 (mAb 6303) (Medix
Biochemica, Kauniainen, Finland), total and phospho GCN2 (Abcam, Cambridge, MA,
USA)pre-validatedcustom phosphosite-specific IGFBP-1 polyclonal antibodies targeting
pSer101, pSer119, and pSer169 (generated at YenZyme Antibodies LLC, San Francisco,
CA, USA). Primary antibodies were all used at a dilution of 1:1000, and peroxidaselabelled goat-anti mouse or goat-anti rabbit antibodies (1:10000, BioRad Laboratories
Inc.) were used as secondary antibodies. Band intensities were determined using
densitometry in Image Lab (Beta 3) software (BioRad).
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2.2.7 Validation of custom phosphosite-specific IGFBP-1 antibodies
In our previous study56, four IGFBP-1 mutants with single amino acid substitutions
(Ser98Ala, Ser101Ala, Ser119Ala and Ser169Ala) were generated that disrupted IGFBP1 phosphorylation. We used these well-characterized mutants and wild-type (positive
control) IGFBP-1 and performed western blots using our custom phosphosite-specific
IGFBP-1 antibodies (pSer101, 119 and pSer169) as primary antibodies in order to
validate their specificity. The data shown in the Figure 356 using pSer101 and pSer169specific antibodies clearly validate that the pS101 antibody only recognized IGFBP-1
when Ser101 was phosphorylated and pSer169 antibody when Ser169 was
phosphorylated. The validity of the IGFBP-1 antibody specific to pSer119 was similarly
reported in a subsequent study in Supplementary Figure 726. The Ser119Ala mutant only
reacted with IGFBP-1 on immunoblot when phosphorylated at Ser119, validating the
specificity of respective antibody. In addition, we used human amniotic fluid (AF) as an
additional positive control. We had previously confirmed for IGFBP-1 phosphorylation at
Ser101, Ser119 and Ser169 residues in amniotic fluid56-58. To include appropriate
negative controls, we utilized alkaline phosphatase (ALP)-treated amniotic fluid, wildtype and mutant IGFBP-1 samples to demonstrate diminished reactivity with IGFBP-1
following ALP treatments56-59. These data unequivocally demonstrate that our custom
phosphosite-specific IGFBP-1 antibodies are highly specific to only phosphorylated
forms of IGFBP-1 at their respective sites.

2.2.8 IGF-I receptor activation assay
P6 cells (a gift from Dr. R. Baserga, Thomas Jefferson University, Philadelphia, PA), are
immortalized mouse embryonic fibroblast cells (a BALB/c3T3 cell line) that overexpress human IGF-1R but do not express IGF-I60. Therefore, they are a widely
established model for the assessment of IGF-1R activation under IGF-I addition61,62. We
have tested the validity of P6 cells under conditions of variable IGFBP-1 phosphorylation
previously in our laboratory26,56. P6 cells were cultured in DMEM/F12 with sodium
pyruvate supplemented with 10% FBS.

80
The P6 cell bioassay was performed in FBS-free conditions as we described previously56.
Aliquots of HepG2 cell media from various treatments containing equal concentrations of
IGFBP-1 were buffer-exchanged to P6 cell media using Amicon Ultra0.5 mL Centrifugal Filter Units (Millipore, Darmstadt, Germany) per manufacturer
instructions. Samples were subsequently incubated with rhIGF-I (25 ng/mL) for two
hours at room temperature. P6 cells were treated for 10 minutes with the P6 media
containing IGFBP-1/IGF-I complexes. Cells were subsequently lysed and samples were
separated using SDS-PAGE gels and immunoblot analysis was performed to asses IGF1R autophosphorylation using phosphosite-specific IGF-1Rβ (Tyr1135) primary
antibody.

2.2.9 Data presentation and statistics
Data was analyzed using GraphPad Prism 5 (Graph Pad Software Inc., CA). Three
replicates were analyzed for each treatment condition, including the control treatment.
For each quantified protein, the mean density of the control sample bands was assigned
an arbitrary value of 1, and averaged densitometry values for each treatment were
expressed relative to this mean. We employed One-way analysis of variance with
Dunnet’s Multiple Comparison Post-Test and expressed results as the mean ± Standard
Error of Measurement (SEM). Significance was accepted at *p<0.05. n=3.

2.3

Results

2.3.1 Rapamycin and/or leucine deprivation inhibit mTOR signaling
First, we assessed changes in mTORC1 and C2 signaling in response to leucine
deprivation and rapamycin as a pharmacological mTOR inhibitor. Based on our previous
dose dependencydatafor leucine deprivation in HepG2 cells25, we cultured HepG2 cells in
media with leucine (450 μM) or deprived of leucine (0 μM). Cells were cultured with or
without rapamycin (100 nM). We assessed changes in mTORC1 and C2 signaling
activity in response to leucine deprivation and/or rapamycin by investigating changes in
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phosphorylation of downstream effectors p70-S6K (Thr389) and Akt (Ser473) as
functional readouts of mTORC1 and C2 activity, respectively.
As evidenced in Figure 2.1A-B, we noted a significant decrease in mTORC1 and C2
activity by leucine deprivation, rapamycin treatment, and leucine deprivation and
rapamycin combined, indicated by decreased phosphorylation (-60%) of p70-S6K
(Thr389) and Akt (Ser473) (-65-70%) under these three treatments. These data
demonstrate that both mTORC1 and C2 activity are significantly inhibited by rapamycin.
In addition, leucine deprivation inhibited mTORC1 and C2 activity to the same extent as
rapamycin with no additive effect when the two treatments were combined (Figure 2.1AB), supporting that the degrees to which mTORC1 and C2 were inhibited were not
significantly different between treatments.

2.3.2 mTOR inhibition increases IGFBP-1 secretion but not IGFBP-1
phosphorylation in leucine deprivation
To test our hypothesis that mTOR signaling is responsible for changes in IGFBP-1
secretion and phosphorylation in amino acid limitation, we first investigated the effects of
rapamycin and leucine deprivation on IGFBP-1 secretion and phosphorylation in HepG2
cells singly and combined. To examine these changes, we resolved equal volumes of
HepG2 cell media from rapamycin-treated cells with leucine (450 μM) or in leucine
deprived (0 μM) conditions (Figure 2.1C-F). As demonstrated in Figure 2.1C, IGFBP-1
secretion was increased (+400%) both in leucine deprivation and rapamycin and these
effects were not additive when both treatments were combined. To investigate whether
this effect was consistent with IGFBP-1 phosphorylation, we used custom phosphositespecific IGFBP-1 antibodies against pSer101, pSer119 and pSer169 (Figure 2.1D-F). We
demonstrated that while rapamycin consistently induced IGFBP-1 phosphorylation
(Ser101, +400%, Ser119, +200% and Ser169, +400%), leucine deprivation increased
IGFBP-1 phosphorylation beyond that seen by rapamycin treatment alone (Ser101,
+1000%, Ser119, +500% and Ser169, +1200%) (Figure 2.1D-F). Further, there was no
additive effect on IGFBP-1 phosphorylation at any of the three sites in combined leucine
deprivation and rapamycin treatment compared to leucine deprivation alone (Figure
2.1D-F), suggesting that mTOR signaling does not induce IGFBP-1 phosphorylation in a
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parallel mechanism, but rather contributes partially to IGFBP-1 phosphorylation induced
by leucine deprivation. Together, these findings strongly suggest that while leucine
deprivation inhibited mTOR signaling to the same extent as rapamycin, changes in
IGFBP-1 phosphorylation under nutrient deprivation are only in part regulated by mTOR
signaling. While mTOR inhibition was sufficient to induce total IGFBP-1 secretion to the
same extent as leucine deprivation, IGFBP-1 phosphorylation due to leucine deprivation
is only partially regulated by mTOR signaling. These data suggest that mTOR signaling
and leucine deprivation function in a common mechanism to induce total IGFBP-1
secretion, additional mechanisms are involved in regulation of IGFBP-1 phosphorylation.
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Figure 2.1. The effect of leucine deprivation and rapamycin on mTORC1+C2
activity and IGFBP-1 secretion and phosphorylation.A representative immunoblot of
HepG2 cell lysate (35 μg per lane) assayed for A. S6K (Thr389) phosphorylation and B.
Akt (Ser 473) phosphorylation. A representative western immunoblot of HepG2 cell
media (40 μL per well) displaying C. total IGFBP-1 secretion and D-F. IGFBP-1
phosphorylated at Ser101, Ser119, and Ser169 in control, leucine deprivation, rapamycin,
and combined leucine deprivation+rapamycin treatments. Values are displayed as mean +
SEM. *p<0.05, **p=0.001-0.05, ***p <0.001 versus control; One-way analysis of
variance, Dunnet’s Post-Test. n=3. C: Control, 450 μM leucine. LD: Leucine deprivation,
0 μM leucine. R: Rapamycin (100 nM), 450 μM leucine. R:LD: Rapamycin (100 nM), 0
μM leucine.
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2.3.3 Inhibition of mTOR signaling by raptor and rictor silencing
confirms that mTOR induces IGFBP-1 secretion, but not
phosphorylation during leucine deprivation
For selective inhibition of mTOR complexes, we employed an RNAi strategy to silence
both raptor and rictor in leucine or leucine deprived conditions with HepG2 cells.
Primarily, we confirmed efficient silencing of both raptor (-45 to 50%) and rictor (-50%)
(Appendix A; Supplementary Figure2.1A-B). Raptor+rictor silencing successfully
inhibited mTORC1 activity as seen by reduced (-50%) phosphorylation of p70-S6K
(Thr389) to a similar extent as leucine deprivation or combined leucine deprivation and
raptor+rictor silencing (Figure 2.2A). Similarly, mTORC2 activity was reduced to a
similar extent in leucine deprivation, raptor+rictor silencing and combined leucine
deprivation and raptor+rictor silencing as assessed by a reduction (-50%) in
phosphorylation of Akt (Ser473) (Figure 2.2B). We therefore confirmed the ability of
raptor+rictor silencing to effectively inhibit mTORC1 and C2 signaling.
Next, we sought to assess whether raptor+rictor silencing translated to changes in
IGFBP-1 secretion and phosphorylation. We demonstrated that raptor+rictor silencing
induced total IGFBP-1 secretion (+350%) to levels comparable to leucine deprivation
with or without raptor+rictor silencing (+400%), and that combined raptor+rictor
silencing and leucine deprivation had no additive effect on IGFBP-1 secretion compared
to leucine deprivation alone (Figure 2.2C). As expected, raptor+rictor silencing induced
IGFBP-1 phosphorylation at all three sites (Ser101, +400%, Ser119, +200% and Ser169,
+400%) but was unable to achieve the phosphorylation induced in the presence of leucine
deprivation (Ser101, +2000%, Ser119, +1100% and Ser169, +2300%) (Figure 2.2D-F).
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2.3.4 Activation of mTORC1 and C2 signaling by DEPTOR silencing
attenuates leucine deprivation-induced IGFBP-1 secretion but
not phosphorylation
To further study changes in IGFBP-1 secretion and phosphorylation under mTOR
signaling, we selectively activated the mTOR pathway using siRNA against DEPTOR, an
endogenous inhibitor against mTORC1 and C2 activity. To maximize cell viability,
serum free DMEM/F12 media containing transfection reagent was aspirated immediately
following the 24 hour transfection period. Cell media were subsequently replaced with
DMEM with (450 μM) or without (0 μM) leucine for an additional 72 hours. We first
confirmed that our RNAi approach efficiently reduced (-50%) DEPTOR expression
(Appendix A; Supplementary Figure 2.1C). Analysis of cell lysates was used to examine
changes in phosphorylation of downstream mTOR effectors (Figure 2.2A-B). DEPTOR
silencing successfully induced p70-S6K (pThr389) phosphorylation (+250%) (Figure
2.2A) and Akt (pSer473) phosphorylation (+300%) (Figure 2.2B) regardless of leucine
status, supporting that constitutive activation of the mTOR pathway induces mTORC1
and C2 signaling downstream of leucine deprivation.
We proceeded to test whether mTOR activation was able to prevent changes in IGFBP-1
secretion and phosphorylation caused by leucine deprivation. Activating mTOR signaling
by DEPTOR silencing successfully attenuated leucine deprivation-induced IGFBP-1
secretion (+400%) (Figure 2.2C) but was unable to prevent leucine deprivation-induced
phosphorylation of IGFBP-1 at all three sites (Figure 2.2D-F). Since mTORC1 and C2
inhibition induced total IGFBP-1 secretion only to the same extent as leucine deprivation,
and since mTORC1 and C2 activation completely prevents this induction, we assert that
mTOR signaling is the key mechanism implicated in IGFBP-1 secretion, but not
phosphorylation, induced by leucine deprivation.

88

Relative p70-S6K phosphorylation (Thr389)
(arbitrary units)

A

(Thr389)

70 kDa

pS6K

70 kDa

S6K

42 kDa

β-actin

4

***
3

**

2

*

*

*

Sc:LD

RR

RR:LD

1
0
Sc

D

D:LD

Relative AKT phosphorylation (Ser473)
(arbitrary units)

B

(Ser473)

56 kDa

pAkt

56 kDa

Akt

42 kDa

β-actin

4

***

***

3
2
1

*

*

Sc:LD

RR

**

0
Sc

RR:LD

D

D:LD

89

C

30 kDa

IGFBP-1

Relative IGFBP-1 secretion
(arbitrary units)

6

***

***
*

4

2

0
Sc

Sc:LD

RR

RR:LD

D

D:LD

D

(Ser101)

Relative IGFBP-1 phosphorylation (Ser101)
(arbitrary units)

30 kDa

pIGFBP-1

40

***

30

***

**

20

10

*
0
Sc

Sc:LD

RR

RR:LD

D

D:LD

90

F

E

(Ser119)

pIGFBP-1

20

15

*

*

*

*

*

*

10

*
*

*

*

5
*
*

0
Sc

Sc:LD

*
RR

RR:LD

D

D:LD

(Ser169)

pIGFBP-1

30 kDa

Relative IGFBP-1 phosphorylation (Ser169)
(arbitrary units)

Relative IGFBP-1 phosphorylation (Ser119)
(arbitrary units)

30 kDa

30

*

20

*

*

*

*

*

*

10

*

0
Sc

Sc:LD

RR

RR:LD

D

D:LD

Figure 2.2. The effect of raptor+rictor or DEPTOR silencing on IGFBP-1 secretion
and phosphorylation in leucine deprivation.A representative western immunoblot of
HepG2 cell lysates (35 μg per lane) displaying A. S6K (Thr389) phosphorylation and B.
Akt (Ser473) phosphorylation. A representative western immunoblot of C. total IGFBP1 secretion and D-F. IGFBP-1 phosphorylation at Ser101, Ser119 and Ser169 in equal
amounts (40 μL per well)of cell media of scrambled, raptor+rictor, DEPTOR siRNA with
and without leucine deprivation in HepG2 cells. Values are displayed as mean +
SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; One-way analysis of
variance; Dunnet’s Multiple Comparison Test; n=3.Sc: Scrambled siRNA, 450 μM
leucine. Sc:LD: Scrambled siRNA, 0 μM leucine (Leucine Deprivation). RR:
Raptor+Rictor siRNA, 450 μM leucine. RR:LD: Raptor+Rictor siRNA, 0 μM leucine. D:
DEPTOR siRNA, 450 μM leucine. D:LD: DEPTOR siRNA, 0 μM leucine.
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2.3.5 Inhibition of AAR (MEK/ERK) signaling attenuates the amino
acid response triggered by leucine deprivation
To investigate stress-responsive pathways other than mTOR that may be involved in
regulating IGFBP-1 phosphorylation under leucine deprivation, we inhibited AAR
signaling, which is activated under cellular amino acid deprivation42,46,63. To chemically
inhibit AAR signaling, we used AAR (MEK1/2) inhibitor U0126 (10 μM) since MEK
signaling is necessary for GCN2-mediated eiF2α phosphorylation (pSer51) and
subsequent propagation of the AAR55. We tested the effects of U0126 on leucinemediated IGFBP-1 secretion and phosphorylation.
GCN2 was activated, as indicated by an increase in phosphorylation of GCN2 (Thr898),
under leucine deprivation (+200%) regardless of MEK status (Figure 2.3A). Leucine
deprivation also induced MEK activity proportionate to GCN2 as indicated by increased
ERK phosphorylation (Thr202/Tyr204) (+200%), which was on the contrary decreased in
the presence of U0126 (-50%) regardless of leucine status (Figure 2.3B).
Figures 2.3C-D indicate that leucine deprivation and subsequent GCN2 activation further
stimulate the AAR as evidenced by an increase in eiF2α (Ser51) phosphorylation
(+150%) and total ATF expression (+200%) in leucine deprived samples. However, AAR
(MEK/ERK) inhibition with U0126 was successful in preventing leucine deprivationinduced AAR propagation downstream of GCN2. We concluded this because in the
presence of the inhibitor, leucine deprivation was unable to induce eiF2α phosphorylation
(Ser51) and ATF4 expression beyond control values (Figure 2.3C-D). Together, these
data advocate the importance of MEK/ERK signaling in AAR propagation and confirm
that chemical inhibition of AAR (MEK1/2) is sufficient in attenuating the AAR cascade.

2.3.6 AAR (MEK/ERK) inhibition prevents leucine deprivation-induced
IGFBP-1 secretion and phosphorylation
We assessed whether attenuation of the AAR results in changes in downstream IGFBP-1
secretion and phosphorylation. Total IGFBP-1 secretion was induced (+200%) in leucine
deprivation and reduced (-50%) in the presence of U0126, regardless of leucine status
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(Figure 2.3E). IGFBP-1 phosphorylation was strongly induced (Ser101, +700%, Ser119,
+250% and Ser169, +900%) under leucine deprivation and reduced (-50%) at all three
sites regardless of leucine status when AAR (MEK/ERK) was inhibited (Figure 2.3F-H).
Importantly, the presence of inhibitor did not allow leucine deprivation to induce IGFBP1 secretion (Figure 2.3E) or phosphorylation at any of the three phosphosites (Figures
2.3F-H). To validate changes in IGFBP-1 secretion and phosphorylation, we performed
the Trypan Blue exclusion assay and demonstrated no significant change in posttreatment cell viability between treatment conditions (Appendix A; Supplementary
Figure 2).
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Figure 2.3. Effect of pharmacological AAR inhibitor U0126 (MEK1/2) on IGFBP-1
secretion and phosphorylation.A. Representative western immunoblot of HepG2 cell
lysates (50 μg per lane) tested for GCN2 (Thr898) phosphorylation. A representative
western immunoblot of HepG2 cell lysates (35 μg per lane) display B. ERK
(Thr202/Tyr204) phosphorylation and C. eiF2α (Ser51) phosphorylation and in leucine
deprivation and U0126 treatments. D. Representative western immunoblot of total ATF4
expression (50 μg per lane). Representative western immunoblots indicating E. total
IGFBP-1 secretion and F-H. IGFBP-1 phosphorylation at Ser101, Ser119, and Ser169.in
HepG2 cell media in control, leucine deprivation, U0126, and leucine deprivation+U0126
treatments. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p <
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0.001 versus control; One-way analysis of variance; Dunnet’sMultipleComparisonTest;
n=3.C: Control, 450 μM leucine. LD: Leucine deprivation, 0 μM leucine. U: U0126 (10
μM), 450 μM leucine. U:LD: U0126 (10 μM), 0 μM leucine.
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2.3.7 siRNA silencing of ERK (to inhibit ERK-mediated AAR)
prevents leucine deprivation-induced IGFBP-1 secretion and
phosphorylation
To determine that changes in IGFBP-1 secretion and phosphorylation under leucine
deprivation and inhibition by U0126 were specific and that effects were targeted, in a
subset of experiments, cells were treated with siRNA against ERK to attenuate ERKmediated AAR signaling. First, we validated ERK silencing efficiency by assessing cell
lysates for total ERK expression (-45%) (Appendix A; Supplementary Figure 3). GCN2
phosphorylation (Thr898) was induced by leucine deprivation (+200%) regardless of
ERK status (Figure 2.4A). Although leucine deprivation triggered AAR signaling, it was
not stimulated downstream of GCN2 in cells where ERK was silenced as seen by a lack
of induction in eiF2α phosphorylation (Ser51) and ATF4 expression, which were
otherwise both triggered (+200%) in leucine deprivation (Figure 2.4B-C).
We examined whether ERK silencing (to inhibit ERK-mediated AAR) was able to
attenuate IGFBP-1 secretion and phosphorylation in HepG2 cells. IGFBP-1 secretion and
phosphorylation at all three sites (Ser101, Ser119, and Ser169) was not significantly
different from control values in the presence or absence of leucine when ERK was
silenced (Figures 2.4D-G), supporting our finding that IGFBP-1 secretion and
phosphorylation under leucine deprivation is mediated by the AAR in a MEK/ERK
dependant mechanism.
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Figure 2.4. Effects of ERK siRNA on IGFBP-1 secretion and phosphorylation.
Representative western immunoblots of HepG2 cell lysates (50 μg per lane) treated with
scrambled or ERK siRNA with or without leucine deprivation displayingA. GCN2
(Thr898) phosphorylation,B.eiF2α (Ser51) phosphorylation andC. total ATF expression.
A representative western immunoblot of D.total IGFBP-1 secretion and E-G. IGFBP-1
phosphorylation at Ser101, Ser119 and Ser169 in equal amounts of cell media of HepG2
cell media treated with scrambled or ERK siRNA with and without leucine deprivation.
Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus
control; One-way analysis of variance; Dunnet’sMultipleComparisonTest; n=3.Sc:
Scrambled siRNA, 450 μM leucine. Sc:LD: Scrambled siRNA, 0 μM leucine (Leucine
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Deprivation). ERK: ERK1/2 siRNA, 450 μM leucine. ERK:LD: ERK1/2 siRNA, 0 μM
leucine.

99

2.3.8 AAR inhibition via GCN2 silencing and ERK inhibition (to inhibit
ERK-mediated AAR) act in a common mechanism to regulate
IGFBP-1 secretion and phosphorylation in leucine deprivation
To investigate that MEK/ERK inhibition-mediated regulation of IGFBP-1 secretion and
phosphorylation functions in accordance with the AAR, we inhibited AAR signaling via
GCN2 silencing in tandem with MEK/ERK signaling and assessed changes in
downstream AAR effectors and IGFBP-1 secretion and phosphorylation. We used siRNA
to knockdown GCN2 to prevent AAR-sensing, separately and together with ERK siRNA.
We first confirmed GCN2 (-50%) and ERK (-50%) knockdown efficiency using cell
lysates (Appendix A; Supplementary Figure 4A-B). GCN2 and ERK silencing, separately
and together, prevented AAR propagation downstream of GCN2 as seen by a lack of
increase in eiF2α phosphorylation (Ser51) and ATF4 expression in leucine deprivation by
cells silenced for GCN2 and/or ERK, both of which were otherwise induced (+200%) by
leucine deprivation (Figure 2.5A-B). Silencing of either or both proteins also attenuated
the induction of IGFBP-1 secretion and phosphorylation in leucine deprivation (Figure
2.5C-F). Interestingly, there was no additional reduction in IGFBP-1 secretion or
phosphorylation in leucine plus or leucine deprived samples when both pathways were
inhibited simultaneously (Figure 2.5C-F) suggesting that MEK/ERK signaling and the
AAR function in a common mechanism to regulate both IGFBP-1 secretion and
phosphorylation in leucine deprivation.
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Figure 2.5. Effects of ERK and/or GCN2 silencing on IGFBP-1 secretion and
phosphorylation. A. eiF2α (Ser51) phosphorylation and B. total ATF4 expression in
HepG2 cell lysates silenced with GCN2 and/or ERK siRNA with or without leucine
deprivation. A representative western immunoblot of C. total IGFBP-1 secretion and DF. IGFBP-1 phosphorylation at Ser101, Ser119 and Ser169 in equal amounts (40 μL per
lan)e of cell media of HepG2 cells treated with scrambled, ERK, GCN2, or combined
ERK+GCN2 siRNA with and without leucine deprivation.) treated with scrambled, ERK,
GCN2, or ERK+GCN2 siRNA with or without leucine deprivation.Values are displayed
as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; One-way
analysis of variance; Dunnet’sMultipleComparisonTest; n=3. Sc: Scrambled siRNA, 450
μM leucine. Sc:LD: Scrambled siRNA, 0 μM leucine (Leucine Deprivation). GCN2:
GCN2 siRNA, 450 μM leucine. GCN2:LD: GCN2 siRNA, 0 μM leucine. ERK: ERK1/2
siRNA, 450 μM leucine. ERK:LD: ERK1/2 siRNA, 0 μM leucine. G:E: GCN2+ERK1/2
siRNA, 450 μM leucine. G:E:LD: GCN2+ERK1/2 siRNA, 0 μM leucine.
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2.3.9 IGFBP-1 phosphorylation induced by leucine deprivation is
mediated by CK2
We have hereby established that the AAR is responsible for mediating total IGFBP-1
secretion as well as IGFBP-1 phosphorylation in leucine deprivation, and that mTOR
signaling partially regulates IGFBP-1 phosphorylation but is the key mechanistic link
between nutrient deprivation and total IGFBP-1 secretion. Based on previous data from
our lab26 that CK2 mediates mTOR-induced IGFBP-1 phosphorylation, we investigated
whether CK2 is also involved in leucine deprivation-mediated IGFBP-1 phosphorylation.
We inhibited CK2 signaling using CK2 inhibitor TBB (1 µM) as previously26 in leucine
plus or leucine deprived media. Following treatments, evaluation of HepG2 cells
indicated intact cellular morphology, and Trypan Blue exclusion assay demonstrated that
TBB treatments did not significantly alter the vitality of HepG2 cells (Appendix A;
Supplementary Figure S5), supporting that normal cell physiology was intact posttreatment.
Leucine deprivation significantly induced total IGFBP-1 secretion (+250 to 300%)
regardless of whether they were treated with TBB, suggesting that CK2 is not involved in
regulating total IGFBP-1 secretion during leucine deprivation (Figure 2.6A). However,
similar to MEK/ERK- dependent AAR inhibition, TBB prevented the phosphorylation of
IGFBP-1 at all three sites as seen by an overall reduction (-60%) of IGFBP-1
phosphorylation (Ser101, Ser119 and Ser169) in TBB-treated cells and no significant
increase in phosphorylation in leucine deprived versus leucine plus samples when both
are treated with TBB (Figure 2.6B-D). Therefore, since inhibition of CK2 activity
attenuated leucine deprivation-induced IGFBP-1 phosphorylation without affecting total
IGFBP-1 secretion, we assert that CK2 may potentially be the major kinase responsible
for IGFBP-1 phosphorylation under conditions of leucine deprivation.
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Figure 2.6. Effect of CK2 inhibition on IGFBP-1 secretion and phosphorylation. A.
A representative blot of equal volumes of HepG2 cell media (40 μL per lane) treated with
leucine plus (control), leucine deprivation, TBB (1 μM), or leucine deprivation+TBB. BD. Representative western immunoblots of equal volumes of HepG2 cell media assessed
for IGFBP-1 phosphorylation at Ser101, Ser119, and Ser169. Values are displayed as
mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.0001 versus control; One-way
analysis of variance; Dunnet’s Multiple Comparison Test; n=3. C: Control, 450 μM
leucine. LD: Leucine deprivation, 0 μM leucine. TBB: TBB (1 μM), 450 μM leucine.
TBB:LD: TBB (1 μM), 0 μM leucine.
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2.3.10

Increases in IGFBP-1 phosphorylation due to leucine
deprivation inhibit IGF-I bioactivity

To assess whether changes in IGFBP-1 phosphorylation under leucine deprivation
effectively regulate IGF-I bioactivity, we employed an IGF-1 receptor (IGF-1Rβ)
autophosphorylation assay in P6 cells to test for IGF-1Rβ (Tyr1135)
autophosphorylation26,56 as an indicator of IGF-I bioactivity during leucine deprivation.
When P6 cells were incubated with 25 ng/mL IGF-I only (positive control), we observed
a drastic increase in IGF-1R phosphorylation (Tyr1135) (+2500%) compared to P6 cells
without IGF-I (negative control) (Figure 2.6), demonstrating the ability of IGF-I to
stimulate IGF-1Rβ autophosphorylation in P6 cells. P6 cells were also treated with IGF-I
plus post-treatment HepG2 cell media (leucine plus or leucine deprivation). The amount
of leucine plus or leucine deprivation media used in the treatment was adjusted for total
IGFBP-1 and buffer-exchanged to P6 cell media as described above (Section 2.3.6) to
ensure that changes in IGF-1Rβ phosphorylation were not due to differences in media
composition.
When P6 cells were incubated with IGFBP-1 from HepG2 cells with 450 µM leucine
(basal) media+IGF-I (control), a significant reduction in IGF-1R autophosphorylation
was observed (-40%) compared to P6 cells incubated with IGF-I only. This suggests that
basal levels of IGFBP-1 secreted by HepG2 cells were able to sequester bioavailable
IGF-I and subsequently reduce IGF-1R signaling. On the other hand IGF-I induced IGF1Rβ phosphorylation was almost completely abolished (-90%) when HepG2 cell media
from leucine deprivation (0 µM leucine) was used. These data suggest that IGF-1Rβ
phosphorylation was inhibited due to the presence increase in IGFBP-1 phosphorylation
due to leucine deprivation (Figure 2.6). Considering equal concentration of total IGFBP-1
from HepG2 cell media incubated with IGF-I was used to activate IGF-1R in P6 cells for
each of the treatments, these data support that the hyperphosphorylation of IGFBP-1 in
leucine deprivation effectively inhibits IGF-I bioactivity through reduced IGF-1Rβ
autophosphorylation (pTyr1135).
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Figure 2.7. The effect of leucine deprivation-induced IGFBP-1 phosphorylation on
IGF-1R autophosphorylation.HepG2 cells were treated in leucine plus (450 μM Leu) or
leucine deprived (0 μM Leu) for 24 hours. Equal concentrations of IGFBP-1 in HepG2
cell media were mixed with P6 media (serum free) and human recombinant IGF-I (25
ng/mL) for 2 hours to allow IGFBP-1 to sequester IGF-I. Ten minute exposure to P6 cells
allowed the induction of IGF-I-mediated IGF-1Rβ autophosphorylation (Tyr1135). A
representative western immunoblot of cell lysates (50 μg per lane) from P6 cells overexpressing IGF-IR. Blots were assessed for IGF-IR autophosphorylation (Tyr1135).
Increased IGFBP-1 phosphorylation due to leucine deprivation results in significantly
decreased IGF-1R activation. Values are displayed as mean + SEM. *p< 0.05, **p=
0.001-0.05, ***p < 0.001 versus control; One-way analysis of variance;
Dunnet’s Multiple Comparison Test; n=3. – IGF-I: Negative control, no IGF-I, no
IGFBP-1. +IGF-I: Positive control, 25 ng/mL IGF-I, no IGFBP-1. 450 μM leucine +
IGF-I: IGFBP-1 from HepG2 cell media with leucine plus 25 ng/mL IGF-I. 0 μM leucine
+ IGF-I: IGFBP-1 from HepG2 cell media without leucine plus 25 ng/mL IGF-I.
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2.4

Discussion

In this study, we use HepG2 cells, to show for the first time that the AAR regulates
IGFBP-1 secretion and phosphorylation at Ser101, Ser119 and Ser169 in amino acid
deprivation. Although mTOR inhibition induced IGFBP-1 secretion in leucine
deprivation, it failed to increase IGFBP-1 phosphorylation to the levels induced by
leucine deprivation alone. Activation of mTOR validated these findings, suggesting that
mTOR regulates IGFBP-1 secretion but not IGFBP-1 phosphorylation in leucine
deprivation. However, when the AAR was blocked, it prevented both IGFBP-1 secretion
and phosphorylation in response to leucine deprivation. These findings are consistent
with our hypothesis that mTOR inhibition and AAR activation increase IGFBP-1
secretion and phosphorylation independently in response to amino acid deprivation. This
study provides a novel understanding of the mechanisms modulating IGF-I
bioavailability and potentially fetal growth under reduced amino acid availability in FGR.
Nutrient deprivation is a leading cause of FGR2,27, a perinatal disorder which increases
the risks of both severe childhood and adult metabolic and neurological complications.
IGF-I is the key regulator of fetal growth beginning at ~16-20-weeks gestation64,65 and its
altered circulating levels during gestation are correlated with fetal growth
complications66-68. IGF-I bioavailability is strongly influenced by the phosphorylation
status of IGFBP-169. Previous literature reports 59,70,71 including ours26,57,58 indicate strong
association of IGFBP-1 phosphorylation with altered fetal growth. Mimicking hypoxia
and leucine deprivation in HepG2 cells, the two key conditions associated with human
FGR in vivo, we have previously demonstrated site-specific hyperphosphorylation of
IGFBP-1 in vitro25. Furthermore, our previous data have also shown that increase in
phosphorylation of IGFBP-1 at specific sites (Ser101, Ser119 and Ser169) in human
amniotic fluid to be associated with increased binding affinity for IGF-I in FGR57. These
data provided strong rationale to determine the mechanistic details of how IGFBP-1
phosphorylation is controlled in restriction of fetal growth such as due to lack of nutrient
availability in FGR.
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FGR is characterized by decreased amino acid availability2,21,27,72 which is known to
activate the AAR44,63 and inhibit the mTOR signaling pathway29,41. We investigated the
two regulatory pathways (AAR and mTOR), to determine the mechanism linking reduced
nutrient availability to IGFBP-1 secretion and phosphorylation and consequently, reduced
IGF-I bioavailability and downstream IGF-I bioactivity via assessing changes in IGF-1R
autophosphorylation.
We utilized HepG2 cells in this study as a well-established model for human fetal
hepatocytes50-54. The HepG2 and fetal hepatocyte transcriptomes54,73,74 and
secretomes38,50,53,75 are highly similar. Moreover, we have shown that HepG2 cells are
also highly responsive to hypoxia and leucine deprivation25. In addition we have tested
the validity of our data with IGFBP1 using well-characterized76 fetal primary baboon
hepatocytes26
The mTOR pathway modulates cell growth and function in response to changes in the
levels of growth factors, such as IGF-I and nutrients, and is down-regulated under
reduced cellular energy states29,30,37,40,41. Our results with pharmacological inhibitor
(rapamycin) and RNAi based inhibition of mTORC1 and C2 signaling have previously
demonstrated induced IGFBP-1 secretion and phosphorylation in HepG2 cells26. In the
present study, our new findings demonstrated that while mTOR signaling plays a vital
role in regulating IGFBP-1 secretion, interestingly, leucine deprivation impinges on
additional mechanisms to produce its downstream stress response on IGFBP-1 secretion
and phosphorylation.
Dietary protein restriction significantly induces hepatic IGFBP-1 mRNA expression in
rats77 and is consistently reduced in human circulation in conditions of reduced nutrient
intake78,79. It has also been reported that leucine deprivation is sufficient in inducing
maximal IGFBP-1 mRNA expression compared to the individual or combined restriction
of any other essential amino acid80. It is well established that the AAR signal transduction
pathway is activated by limitation or imbalance of essential amino acids40,42-47. It has also
been previously shown that deprivation of a single essential amino acid, leucine, is
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sufficient to induce AAR activation via GCN2 phosphorylation43. To our knowledge the
role of AAR in regulation of IGFBP-1 phosphorylation has however not yet been
investigated.
In concordance with literature reports55, we showed that leucine deprivation activated the
AAR, as expected, and that this effect was attenuated downstream of GCN2 when
MEK/ERK was inhibited. Attenuating the AAR via MEK/ERK and/or GCN2
inhibition/silencing clearly prevented induction of both IGFBP-1 secretion and
phosphorylation due to leucine deprivation; this importantly shows that the mitogenic
MEK/ERK cascade mediates leucine deprivation-induced IGFBP-1 secretion and
phosphorylation via its interactions with the AAR pathway. This cross-talk is vital in
transducing the AAR and elucidating downstream changes in IGFBP-1 secretion and
phosphorylation, suggesting that MEK/ERK-dependant AAR signaling is the key
mechanism involved in fetal hepatic IGFBP-1 phosphorylation, and consequently,
regulation of IGF-I bioavailability. Since inhibition of the AAR was sufficient to
attenuate this response, we assert that IGFBP-1 secretion and phosphorylation is
regulated primarily by the AAR in a MEK-dependant manner while mTOR contributes a
significant role in regulation of IGFBP-1 secretion. It is unclear whether the AAR and
mTOR signaling function in common or parallel mechanisms to regulate IGF-I
bioavailability and bioactivity. In light of our findings, we propose a model where lack of
amino acid availability inhibits hepatic mTOR signaling while simultaneously inducing
the AAR pathway, leading to an increase in IGFBP-1 phosphorylation and decreased
fetal cell growth and proliferation (Figure 2.8).
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Figure 2.8. Proposed model of fetal growth regulation in FGR. Amino acid limitation
causes a decrease in mTOR signaling which leads primarily to an increase in IGFBP-1
secretion. A concurrent induction in the AAR pathway signals an increase in IGFBP-1
secretion and phosphorylation, to regulate IGF-I bioavailability and decreased
downstream fetal growth.
Although increased total IGFBP-1secretion is a strong indicator of reduced IGF-I
bioavailability, we assert that the pathogenesis of FGR is due primarily to phosphositespecific changes in IGFBP-1 phosphorylation, supported by our earlier data that show
increases (30-300-fold) in IGF-1 affinity to be linked with marked increases in distinct
site-specific IGFBP-1 phosphorylation (Ser101, Ser119, Ser169)25.
Notably, not all serine residues in our study due to leucine deprivation appear to be
equally prone to phosphorylation and this reflects an additional level of complexity of the
regulation of IGF-I bioavailability. For example, it is possible that different types of
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cellular stresses, such as leucine deprivation versus hypoxia, have distinct effects on IGFI bioavailability mediated by different patterns of IGFBP-1 serine phosphorylation25.
Although the true biological significance of the variable degree of phosphorylation at the
different serine residues in response to leucine deprivation remains to be established, we
speculate that induction of phosphorylation at Ser119 under leucine deprivation in this
study possibly acts through synergistic interactions with doubly or multiply
phosphorylated residues which may result in the high affinity of IGFBP-1 for IGF-I.
These synergistic multi-site interactions were not tested in our previous study56 or
elsewhere in the literature. Such interactions would require further experimental evidence
through structure-functional and quantitative mass spectrometry (MRM MS) studies. In
addition, we expect that the relatively weaker induction of phosphorylation at Ser119
compared to Ser101 and Ser169 under leucine deprivation also reflects the functional
characteristics and substrate preference of the protein kinases responsible for
phosphorylating respective serine residues.
The three phosphorylated Ser residues in IGFBP-1 are surrounded by acidic amino acids,
making them conducive to phosphorylation by CK269,81. CK2 has been suggested to be a
kinase that could phosphorylate IGFBP-1 in vitro82. However, we have recently
demonstrated that inhibition of CK2 by pharmacological inhibitor TBB or targeting CK2
holoenzyme using RNAi prevented phosphorylation of IGFBP-1 in HepG2 cells in
culture26. In the current study we further indicate that CK2 is involved in IGFBP-1
phosphorylation under leucine deprivation implicating CK2 as a potential kinase
regulating increased IGFBP-1 phosphorylation under nutrient deprivation. Whether CK2
is the key kinase linking the AAR signaling pathway in fetal liver to IGFBP-1
phosphorylation under leucine deprivation is currently not known.
In conclusion, our findings in this study are consistent with the possibility that the AAR
signaling is involved in pathogenesis of FGR. Levels of essential amino acids are reduced
in FGR fetuses83-86. We have shown, for the first time, that activation of the AAR in the
fetal liver may constitute a key mechanism linking decreased amino acid availability to
decreased IGF-I bioavailability and reduced fetal growth in FGR. To test this hypothesis,
animal models relevant to human FGR, such as our established baboon model of FGR26,
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will be useful. Because of the inaccessibility of the human fetus, implications for the
diagnosis and treatment of FGR are not immediately apparent. However, the decidua
constitutes the primary source of IGFBP-1 in the maternal circulation during
pregnancy87,88, and maternal IGFBP-1 phosphorylation is increased in FGR
pregnancies89. If phosphorylation of decidual IGFBP-1 is regulated by the AAR and
mTOR signaling pathways, our findings may be used in future to develop approaches for
diagnosis and intervention in FGR.
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3

.

Exploring the kinases involved in leucine deprivation-mediated IGFBP-1
phosphorylation
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3.1

Introduction

Fetal Growth Restriction (FGR) predisposes infants to severe childhood and adult
morbidities1,2, making it an important area for investigation. Affecting 5-7% of
pregnancies3, FGR commonly results from insufficient in utero availability of nutrients,
such as oxygen and essential amino acids, to the fetus due to either maternal malnutrition
or inadequate placental nutrient transfer from mother to fetus4-6. The fetal response to
perigestational nutrient deficiency can lead to restricted growth, although the molecular
mechanisms by which this occurs are largely unknown. The insulin-like growth factors
(IGF-I and IGF-II) are critical factors in fetal growth and development across species7-10.
Knockout studies of IGF-I and IGF-II in mice demonstrate that both IGFs are crucial to
fetal growth and development11, and that deficits in IGF-II lead to pathological placental,
embryonic, and organ development as well as fetal demise12,13. IGF-II provides a
continuous stimulus for growth14and exists in the fetal serum in far greater concentrations
(3-10 fold) than IGF-I14,15. However, as gestation progresses, fetal development becomes
increasingly dependent on IGF-I16, whose function is acutely sensitive to physiological
and environmental cues, such as nutritional stress14,17. In human studies, fetal IGF-I
levels in particular have been consistently positively associated with fetal size and birth
weight18-21, and its fetal circulating levels are decreased in growth restricted human
fetuses8,19,21-23. IGF-Binding Protein 1 (IGFBP-1) secreted from the fetal liver24, the
predominant fetal circulating IGFBP in pre-natal life25-28, is a potent inhibitor of IGF-I
bioavailability in vitro and in vivo29-33and functions by sequestering IGF-I from its cellsurface cognate receptor (IGF-1R), preventing downstream cell growth and
proliferation34. Phosphorylated IGFBP-1 isolated from HepG2 cell media, an in vitro
model for fetal hepatocytes35-39 as well as phosphorylated IGFBP-1 from human plasma
demonstrates a 6-10 fold greater affinity for IGF-I compared to the non-phosphorylated
isoform29,40.The phosphorylation status of fetal IGFBP-1 during pregnancy has been
associated with fetal growth abnormalities41-44. Importantly, our team has recently
detected elevated levels of phosphorylated IGFBP-1 (pSer101, pSer119, pSer169) in
umbilical cord plasma45 from FGR babies.
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Previous work in our lab has established that FGR is associated with fetal IGFBP-1
hyperphosphorylation42,45, making it crucial to identify the molecular mechanisms which
mediate amino acid deprivation-induced IGFBP-1 phosphorylation, which, to date, have
not been extensively classified. Leucine depletion stimulates IGFBP-1 phosphorylation
(pSer101, pSer119, pSer169) in HepG2 cells46which we recently demonstrated to be
linked to the activation of the Amino Acid Response (AAR) (Chapter 2). The specific
kinases which phosphorylate IGFBP-1 at Ser101, Ser119, and Ser169 in leucine
deprivation, however, have not been reported.
Initialstudies of the kinases whichphosphorylate IGFBP-1 were conducted in human
endometrial stromal cells derived from pregnant women and cultured in vitro47. Due to
the proximity of IGFBP-1 phospho-serines to acidic residues conducive to
phosphorylation by CK2, and based on the elevated presence of PKA substrate, cAMP, in
stromal cells47, IGFBP-1 was isolated from cell media from cultured stromal cells and
incubated with purified protein kinase CK2 or protein kinase A (PKA). Both kinases
induced phosphorylation of previously non-phosphorylated IGFBP-1 indicating that CK2
and PKA can phosphorylate IGFBP-1 in vitro47. However, the direct exposure of CK2 or
PKA to IGFBP-1 when the protein and kinases are co-incubated is not reflective of
intracellular conditions; thus, the kinases which phosphorylate IGFBP-1 when coincubated with the substrate do not necessarily represent the kinases which are triggered
intracellularly to phosphorylate IGFBP-1 with high affinity in either regular or nutrient
restricted conditions. Additionally, the distinct IGFBP-1 residues that were
phosphorylated by these kinases were not reported. The proximity of acidic amino acids
(Aspartic Acid (D), Glutamic Acid (E)) to residues Ser101, Ser119, and Ser169 on
IGFBP-1 make them conducive to direct phosphorylation by CK2 (Table 3.1). Ser101
and Ser169 are proximal to structured regions on the IGFBP-1 molecule that contain the
IGF-I-binding domain, whereas Ser119 is contained within the unstructured linker region
that is unique to each IGFBP48. A subsequent study by Ankrapp et. al. demonstrated that
partially purified CK2 from HepG2 cell extracts phosphorylated recombinant human
IGFBP-1 produced by CHO cells in vitro at Ser101 and Ser16949. The functional
relevance of CK2 in phosphorylating IGFBP-1 within live cells, however, was not
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established. CK2 is a pleiotropic kinase with over 300 potential substrates50; therefore, to
establish CK2 as the key, specific kinase implicated in IGFBP-1 phosphorylation in live
cells, it was necessary to specifically inhibit CK2 using both pharmacological and siRNA
approaches and to measure subsequent IGFBP-1 phosphorylation, a strategy which was
recently undertaken in our laboratory in HepG2 cells45.
The recent demonstration by our team that pharmacological (TBB) and siRNA inhibition
of CK2 reduces IGFBP-1 phosphorylation in live, cultured HepG2 cells in addition to the
demonstration that hepatic CK2 activity is elevated in growth-restricted baboon offspring
from mothers who received restricted diets during gestation45, provides strong rationale
for our investigation as to whether CK2 is a direct mechanistic link between amino acid
depletion and IGFBP-1 phosphorylation.
PKA activity is also sensitive to fluctuations in nutrient availability51-56 and reduction in
its activity has been linked to total IGFBP-1 mRNA and protein expression in HepG2
cells57,58. Similarly, overall protein kinase C (PKC) activity is decreased in nutrient
deficiency59-63, and has been linked to elevated IGFBP-1 protein secretion in HepG2
cells64. However, whether PKA and PKC are linked to IGFBP-1 phosphorylation, in
either regular leucine or leucine-deprived conditions, has not been reported. PKC exists
in a variety of isotypes comprising of conventional PKCs (cPKCs: α, βI, βII and γ), novel
PKCs (nPKCs: δ, ε, θ and η) and atypical PKCs (aPKCs: ζ, ν and λ)65 all of which are
dynamically regulated by a variety of intra- and extra-cellular stimuli66. The placental
PKC isoform profile is altered in mice with induced FGR67,68 although the exact function
of each isoform is unknown. Neither PKA nor PKC contain consensus sequence sites for
the direct phosphorylation of the IGFBP-1 protein at Ser101, Ser119 or Ser169 (Table
3.1) despite PKA being implicated as an IGFBP-1 kinase when the purified kinase was
co-incubated with the substrate in vitro47. It is possible that PKA and PKC phosphorylate
IGFBP-1 at additional Ser or Thr residues for which it shares consensus sequence sites
(Table 3.1). IGFBP-1 was previously shown to be phosphorylated at Ser95 and Ser98,
suggesting that additional IGFBP-1 residues in addition to Ser101, Ser119 and Ser169
which are hyperphosphorylated in FGR45,69, may also be prone to phosphorylation70.
PKC or PKA may indirectly modulate IGFBP-1 phosphorylation (Ser101, Ser119 and
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Ser169) in HepG2 cells via phosphorylation at discrete IGFBP-1 residues for which it
shares consensus sequences (Table 3.1), or via up-stream signaling networks which
induce CK2 activity. For example, both kinases have been implicated down-stream of
mechanistic target of rapamycin (mTOR signaling) and may function in a common
signaling mechanism to modulate IGFBP-1 phosphorylation by mTOR, which was
previously demonstrated to mediate IGFBP-1 phosphorylation via CK245.
In this study, we sought to elucidate the roles of CK2, PKC, and PKA in modulating
IGFBP-1 phosphorylation (Ser101, Ser119 and Ser169) in leucine-deprived HepG2 cells,
which have been validated as an in vitro model for human fetal hepatocytes35-39. We
hypothesized that CK2 activity is induced by leucine deprivation and is directly linked to
IGFBP-1 phosphorylation (Ser101, Ser119 and Ser169) in HepG2 cells. We focused on
IGFBP-1 phosphorylation at Ser101, Ser119 and Ser169 because these sites have been
demonstrate to modulate IGFBP-1 affinity for IGF-I42,46,71,72 and have been shown by our
team to be hyperphosphorylated in FGR45,69. Further, based on the down-regulated
activity of the PKCs and of PKA in nutrient restriction which has been demonstrated in
multiple cell types in vitro51-53,59-63, we hypothesized a possible link between PKC and
PKA and IGFBP-1 phosphorylation in leucine deprivation. Due to the fact that Ser101,
Ser119 and Ser169 do not fall in the consensus sequences for PKC or PKA, we predict
that any identified links between PKC or PKA and IGFBP-1 phosphorylation will be
indirect and inflicted via CK2.
To examine the mechanistic links between CK2, PKC and PKA and IGFBP-1
phosphorylation in leucine deprivation, we inhibited CK2, PKC or PKA in regular media
(450 µM leucine, equivalent to standard DMEM/F12) and in leucine deprived (0 µM
leucine, to ensure maximal IGFBP-1 phosphorylation46 conditionsand studied changes in
IGFBP-1 secretion and phosphorylation (pSer101, pSer119 and pSer169) by western
immunoblot analyses of conditioned cell media. To down-regulate overall PKC signaling,
we used non-isoform discriminate PKC inhibitor Bisindolylmaleimide (BIS) and panPKC siRNA, which targets all cPKCs and nPKCs in addition to aPKCζ, and aPKCν. We
attribute functional significance to our findings using our established45,71 IGF-1R
autophosphorylation assay.Whereas direct exposure of purified IGFBP-1 to CK2 or PKA
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demonstrated an ability for the two kinases to phosphorylate IGFBP-1in vitro in earlier
studies47,49, it was not previously studied whether the direct, intracellular inhibition of
these kinases would alter IGFBP-1 phosphorylation in regular (leucine plus) or in
leucinedeprived conditions. These previous investigations did not adequately demonstrate
that CK2 or PKA were linked to IGFBP-1 phosphorylation in live cells; thus, the direct
inhibition of candidate kinases (CK2, PKA, PKC) for IGFBP-1 phosphorylation in
HepG2 cells in this study sought to confirm whether the kinases are essential to leucine
deprivation-mediated IGFBP-1 phosphorylation in vitro. To our knowledge, we provide
the first report of the relative effects of inhibiting CK2, PKA or PKC in modulating
leucine deprivation-induced IGFBP-1 phosphorylation (pSer101, pSer119, and pSer169)
in HepG2 cells, which conclusively illustrate the functional roles of the kinases in
modulating IGFBP-1 phosphorylation in leucine restriction which have not been
previously reported. Identifying the specific intracellular kinases that are linked to
IGFBP-1 phosphorylation in leucine deprivation in cultured HepG2 cells is important to
provide insight into the signaling mechanisms that mediate IGFBP-1 phosphorylation in
leucine deprivation.
Table 3.1. IGFBP-1 peptide sequence (45-180) and possible phosphorylation sites for
CK2, PKC and PKA.
45

ACGVApT50ARCARGLpS58CRALPGEQQPLHALTRGQGACVQESDASAP

IGFBP-1 peptide
sequence (45180)

HAAEAGSPESPEpS101TEITEEELLDNFHLMAPpS119EEDHSILWDAISTYDG
SKALHVTNIKKWKEPCRIELYRVVESLAKAQETpS169GEEISKFYLPN180

CK2: pS/T-X-X-D/E

Kinase
consensus
sequences:

CK2

CK2

PKC: pS/T-X-R/K
PKA: R/K-R/K-X-pS/T

pS101TEITEEE
pS119EED
pS169GEE
pT50AR
pS58CR
NIL

IGFBP-1 residues phosphorylated in HepG2 cells in response to leucine deprivation 46 and in FGR umbilical
cord plasma45 (Ser101, Ser119 and Ser169) are likely sites for phosphorylation by CK2. Conversely, PKC
and PKA are not likely to directly phosphorylate IGFBP-1 at these sites.
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3.2

Methods

3.2.1 Cell culture
Human hepatocellular carcinoma (HepG2) cells were purchased from ATCC
(Mananassas, VA). HepG2 cells were cultured in DMEM/F-12 supplemented with 10%
FBS (Invitrogen Corp., Carlsbad, CA). Cultures were incubated in 20% O2 and 5% CO2
and maintained at 37°C.

3.2.2 Leucine deprivation
HepG2 cell treatments were conducted in specialized DMEM/F12 previously deprived
and restored of specific amino acids46. Cells were incubated in this specialized media
supplemented with 450 µM leucine to mimic leucine concentrations in regular
DMEM/F12 as a control (leucine plus) or in media that was not supplemented with
leucine (0 μM leucine; leucine minus) to ensure maximum induction of IGFBP-1
phosphorylation as previously46. The concentrations of all other amino acids were
consistent between the two sets of media.

3.2.3 Inhibitor treatments
HepG2 cells were plated in 12-well plates and grown to ~75% confluence. After
starvation in 2% FBS (DMEM/F12) for 6 hours, cell media was replaced with specialized
leucine plus or leucine minus media containing the various inhibitors. Concentrations for
BIS (7.5 µM) and PKI 5-24 (PKI) (100 nM) treatments were determined based on dosedependency treatments (Appendix C). Phosphorylation of CREB (Ser133) was used to
assess changes in PKA activity. TBB was used at a concentration of 1 μM as reported
previously71. HepG2 cells were incubated with the inhibitors for 24 hours, after which
cell media and lysates were prepared as previously71.

3.2.4 RNA interference (RNAi) silencing
HepG2 cells were plated in 12-well culture plates and grown to 60% confluence. 5 μL
Dharmafect transfection reagent 4 (Thermo Scientific, Rockford, IL, USA) was used to
transfect 100 nM siRNA against CK2α, CK2α’, CK2β (SMARTpool, Thermo Scientific,
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Rockford, IL, USA) or pan-PKC (against PKC isoforms α, β, βII, γ, δ, ε, η, θ, ζ, and ν)
(Santa Cruz Biotechnology, Dallas, TX, USA) in serum free DMEM/F12 for 24 hours to
ensure maximal silencing efficiency. Transfection media containing the transfection
reagent was removed 24 hours post-transfection. HepG2 cells were subsequently
incubated with specialized leucine plus or leucine minus media for an additional 72
hours. Western immunoblot analysis of CK2α, CK2α’ and CK2β demonstrated effective
silencing of CK2 subunits, whereas immunoblot analysis of PKCδ and PKCε together
represented effective silencing of pan-PKC.

3.2.5 Cell viability assay
To ensure that leucine deprivation and/or chemical BIS did not compromise cell viability,
we employed a trypan bBlue exclusion assay. This confirmed that decreases in IGFBP-1
phosphorylation were not attributable to compromised cell vitality due to exposure to the
treatment stimuli. Following leucine deprivation and/or TBB or BIS treatments, cells
were re-suspended in serum-free DMEM/F12. Cell suspensions were diluted 1:1 with
0.4% trypan blue and counted using the Countess Automated Cell Counter (Life
Technologies, Carlsbad, CA). Cell survival was determined as a ratio of live/total cells.

3.2.6 SDS-PAGE and Western Blotting
Equal amounts of cell lysate protein (40-50 μg) were separated by SDS-polyacrylamide
gel electrophoresis to determine total expression of CK2α, CK2α’, CK2β, PKCδ, PKCε,
CREB, IGF-1Rβ, and phosphorylation of CREB (pSer133), IGF-1Rβ (pTyr1135).
IGFBP-1 secretion and phosphorylation at Ser101, Ser119 and Ser169 by HepG2 cells
was determined by western immunoblot of equal volumes of cell media (40-50 μL). Cell
lysates blots were probed with β-actin primary antibody and bands were used for
normalization. Equal loading of conditioned cell media was verified using fibrinogen
antibody (Appendix D).
To block non-specific protein binding on nitrocellulose membranes, we incubated blots
with 5% skim milk diluted in Tris-buffered saline with 0.1 % Tween-20 (TBST) for 1
hour at room temperature. Alternatively, blots for monoclonal IGFBP-1 were blocked
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with 5% Bovine Serum Albumin in TBST and blots for total CK2α, CK2α’ or CK2β
were blocked in Odyssey Blocking Buffer (LI-COR Biosciences, Bad Homburg,
Germany). Monoclonal anti-human IGFBP-1 (mAb 6303) was obtained from Medix
Biochemica (Kauniainen, Finland) and custom IGFBP-1 polyclonal antibodies against
pSer101, pSer119, and pSer169 were generated at YenZyme Antibodies LLC, San
Francisco, CA, USA. The custom phosphosite-specific antibodies against pSer101 and
pSer169 have been previously validated in the context of non-phosphorylatable IGFBP-1
mutants71. The specificity of phosphosite-specific pSer119 antibody was subsequently
validated in the same manner45. Anti-fibrinogen primary antibody was purchased from
Sigma Aldrich (St. Louis, MO, USA) and antibodies against CK2α, CK2α’ and CK2β
were a kind gift from Dr. D.Litchfield, Western University, London, ON. Remaining
primary antibodies were obtained from Cell Signaling Technologies (Beverly, MA,
USA). All primary antibodies were diluted to 1:1000 with the exception of β-actinwhich
was diluted to 1:3000. Peroxidase-labeled goat-anti mouse or goat-anti rabbit secondary
antibodies were obtained from BioRad Laboratories Inc., and used at a concentration of
1:10000. Densitometric analyses of bands were conducted using Image Lab (Beta 3)
software.

3.2.7 IGF-1 receptor (IGF-1R) activation assay
P6 cells are an immortalized BALB-c3T3 mouse embryo fibroblast cell line derived to
over-express IGF-1R56. We cultured P6 cells in DMEM/F12 with sodium pyruvate,
supplemented with 10% FBS. Post-treatment conditioned HepG2 cell media containing
variable concentrations of total and phosphorylated IGFBP-1 were aliquoted to contain
equal amounts of total IGFBP-1. In addition to leucine plus and leucine minus
conditioned HepG2 cell media which was previously used to assess IGF-1R
autophosphorylation in P6 cells (Chapter 2), we used leucine plus and leucine minus
conditioned media from HepG2 cells which had been incubated with TBB or BIS. In
order to ensure that changes in IGF-1Rβ phosphorylation are caused by differential
degrees of IGFBP-1 phosphorylation rather than total circulating IGFBP-1 or differences
in media composition between treatments, media aliquots were buffer-exchanged to
serum-free P6 cell media (DMEM/F12, with sodium pyruvate) using Amicon Ultra-
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0.5 mL Centrifugal Filter Units (Millipore, Darmstadt, Germany) per manufacturer
instructions. Buffer-exchanged conditioned media were subsequently incubated with
rhIGF-I (25 ng/mL) for two hours at room temperature. P6 cells in 12-well plates were
grown to 75% confluency. For treatment, P6 cells were incubated with prepared media
aliquots for 10 minutes. Following the incubation period, treatment media was aspirated.
Equal amounts of total protein from post-treatment P6 cell lysates were separated using
SDS-polyacrylamide gel electrophoresis. Western immunoblots were used to assess
changes in IGF-1R autophosphorylation (pTyr1135) using phosphosite-specific IGF-1Rβ
(pTyr1135).

3.2.8 CK2 Activity Assay
CK2 activity was measured in HepG2 cell extracts from treatments with leucine
deprivation with and without CK2 inhibitor (TBB) or PKC inhibitor (BIS). As
previously71,73, the synthetic peptide substrate DSD (RRRDDDSDDD)(100 µL) which
was formerly described50 was used to assess CK2 activity. Phosphorus-32 (P32) was
purchased from PerkinElmer (Waltham, MA, USA) and DSD peptide was a kind gift
from Dr. David Litchfield.

3.2.9 Data presentation and statistics
GraphPad Prism 5 (Graph Pad Software Inc., CA) was used for all data analyses. In each
independent experiment, the densitometric values for control bands were averaged, and
this number was assigned an arbitrary value of 1. Densitometric values for each treatment
were averaged among replicates and expressed relative to control. For assessment of
statistical significance, we used one-way analysis of variance (ANOVA) with Dunnet’s
Multiple Comparison Post-Test and expressed results as the mean ± Standard Error of
Measurement (SEM). Significance was accepted at *p<0.05, **p=0.01-0.05, ***p<0.01.
n=3.
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3.3

Results

3.3.1 Silencing of CK2α+α’+β subunits confirms that CK2 contributes
to modulating IGFBP-1 phosphorylation but not secretion
caused by leucine deprivation
Based on our previous datawhich indicate that pharmacological CK2 inhibitor, TBB,
prevents leucine deprivation-induced IGFBP-1 phosphorylation (Chapter 2), we used a
targeted approach (RNAi) to silence the CK2 holoenzyme by siRNA against the three
CK2 subunits (CK2α+α’+β) and assessed changes in total and phosphorylated IGFBP-1
in leucine deprivation. The expression of CK2α and CK2α’ were reduced 45-55% and
CK2β expression was reduced 50-55% (Appendix B; Supplementary Figure 3.1). We
assessed whether CK2 silencing affected leucine deprivation-induced IGFBP-1 secretion
and phosphorylation. Leucine deprivation induced IGFBP-1 secretion (+350%)
regardless of CK2 status (Figure 3.1A). While leucine deprivation induced IGFBP-1
phosphorylation (pSer101: +800%, pSer119: +300%, pSer169: +600%), leucine-deprived
cells also silenced for the CK2 holoenzyme did not phosphorylate IGFBP-1 atany of the
three sites. IGFBP-1 phosphorylation was not significantly elevated in HepG2 cells
which were both CK2-silenced and leucine-starved compared to control (leucine plus,
scrambled siRNA), confirming that leucine deprivation-induced phosphorylation, but not
secretion, occurs in a CK2-dependent mechanism (Figure 3.1A-D).
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Figure 3.1. The effect of CK2 holoenzyme (α+α’+β) silencing on leucine deprivationinduced IGFBP-1 secretion and phosphorylation. Silencing of the CK2 holoenzyme
attenuates IGFBP-1 phosphorylation induced by leucine deprivation. Representative
western immunoblots of HepG2 cell media (50 μL per well) treated with scrambled
siRNA, or siRNA against the CK2 holoenzyme (α+α’+β) in regular leucine plus or
leucine deprived conditions as assessed for A. IGFBP-1 secretion and B. IGFBP-1
phosphorylation at Ser101, Ser119 and Ser169. Values are displayed as mean +
SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; One-way analysis of
variance; Dunnet’s Multiple Comparison Test; n=3. Sc:450: Scrambled siRNA, 450 μM
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leucine. Sc:0: Scrambled siRNA, 0 μM leucine. CK2:450 CK2 holoenzyme (α+α’+β)
siRNA, 450 μM leucine. CK2:0: CK2 holoenzyme (α+α’+β) siRNA, 0 μM leucine.
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3.3.2 Inhibition of PKC signaling with Bisindolylmalemide (BIS)
supports that PKC contributes to the modulation of IGFBP-1
phosphorylation caused by leucine deprivation
We use pharmacological PKC inhibitor Bisindolylmalemide (BIS) (7.5 µM) in leucine
plus or leucine minus conditions in HepG2 cells. A post-treatment Trypan Blue exclusion
assay demonstrated that the vitality of HepG2 cells was not significantly affected by BIS
treatments (Appendix B; Supplementary Figure 3.2), confirming that overt cell mortality
did not contribute to observed changes in total and phosphorylated IGFBP-1 output by
BIS. We assessed whether inhibition of PKC signaling translated to changes in IGFBP-1
secretion and phosphorylation under leucine restriction. We demonstrated that leucine
deprivation induced total IGFBP-1 (+250%) regardless of the presence of BIS (Figure
3.2A). However, while leucine deprivation potently induced IGFBP-1 phosphorylation
(pSer101: +800%, pSer119: +300%, pSer169: +600%) it was unable to achieve the same
effect in the presence of the PKC inhibitor (Figure 3.2B-D). BIS-mediated inhibition of
PKC signaling decreased IGFBP-1 phosphorylation at all three phospho-sites (pSer101: 30%, pSer119: -40%, pSer169: -50%), and leucine deprivation-induced changes in
IGFBP-1 phosphorylation were not significantly different from control in the presence of
BIS (Figures 3.2B-D). These data suggest that PKC signaling is involved in mediating
IGFBP-1 phosphorylation under conditions of leucine deprivation.
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Figure 3.2. Effect of pharmacological pan-PKC inhibitor Bisindolylmaleimide (BIS)
on IGFBP-1 secretion and phosphorylation.BIS prevents IGFBP-1 phosphorylation in
leucine deprivation, demonstrated via representative western immunoblots of HepG2 cell
media indicating A. total IGFBP-1 secretion and B. IGFBP-1 phosphorylation at Ser101,
Ser119 and Ser169 in control, leucine deprivation, BIS, and leucine deprivation+BIS
treatments. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p <
0.001 versus control; One-way analysis of variance;
Dunnet’s Multiple Comparison Test; n=3. C:450 Control, 450 μM leucine. C:0: Leucine
deprivation, 0 μM leucine. BIS:450: Bisindolylmaleimide (7.5 μM), 450 μM leucine.
BIS:0: Bisindolylmaleimide (7.5 μM), 0 μM leucine.
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3.3.3 Silencing of PKC confirms that PKC contributes to modulating
IGFBP-1 phosphorylation caused by leucine deprivation
To confirm PKC involvement in mediating IGFBP-1 phosphorylation in leucine
deprivation, we utilized RNAi to specifically knockdown total PKC expression in HepG2
cells. We utilized non-isoform specific siRNA against PKC (pan-PKC), which targets all
conventional and novel PKC isoforms (cPKCs: α+βI+βII+γ and nPKCs: δ+ε+η+θ) as
well as two out of three atypical PKC isoforms (aPKCs: ζ+ν). cPKCs and nPKCs contain
slight structural differences but, unlike aPKCs, are both equally responsive to
intracellular activation by diacylglycerols (DAGs) and phorbol esters65. We verified
efficient PKC silencing via western immunoblot analysis of two representative PKC
isoforms, nPKCδ and nPKCε, which are known to be down-regulated in nutrient
deprivation61 and with known prominent expression in HepG2 cells74, as a distinct PKC
isoforms profile has not been characterized. The expression of both PKCδ and PKCε
were decreased 50% regardless of leucine status (Appendix B; Supplementary Figure
3.3).
We evaluated the effect of PKC silencing on leucine deprivation-induced IGFBP-1
secretion and phosphorylation. Leucine deprivation induced IGFBP-1 secretion (+450%)
regardless of PKC status (Figure 3.3A). Conversely, PKC silencing strongly attenuated
the ability of leucine deprivation to induce IGFBP-1 phosphorylation, which was
otherwise potently increased (pSer101: +1000%, pSer119: +500%, pSer169: +800%)
(Figure 3.3B-D). IGFBP-1 phosphorylation was only moderately induced by leucine
deprivation when PKC was silenced (pSer101: +400%, pSer119: +250%, pSer169:
+300%). Therefore, silencing of PKC reduces IGFBP-1 phosphorylation in leucine
deprivation at all three sites (pSer101: -60%, pSer119: -50%, pSer169: -70%).
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Figure 3.3. Effects of pan-PKC siRNA on IGFBP-1 secretion and phosphorylation in
leucine deprivation.RNAi-mediated inhibition of PKC mitigates leucine deprivationinduced IGFBP-1 phosphorylation.A. A representative western immunoblot of total
IGFBP-1 secretion in equal amounts (50 µL) of cell media treated with scrambled or
ERK siRNA with and without leucine deprivation. B-D. Representative western
immunoblots of HepG2 cell media (50 µL) treated with scrambled or pan-PKC siRNA in
regular or leucine deprived and assayed for IGFBP-1 phosphorylation at Ser101, Ser119
and Ser169. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p<
0.001
versus
control;
One-way
analysis
of
variance;
Dunnet’s Multiple Comparison Test; n=3.Sc:450 Scrambled siRNA, 450 μM leucine.
Sc:0: Scrambled siRNA, 0 μM leucine. PKC: PKC siRNA, 450 μM leucine. PKC:LD:
PKC siRNA, 0 μM leucine.
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3.3.4 Inhibition of PKA signaling does not affect IGFBP-1
phosphorylation in nutrient deprivation
To investigate whether PKA signaling is involved in regulating IGFBP-1 phosphorylation
under leucine deprivation, we used selective PKA inhibitor, PKI (100 nM), in HepG2
cells in leucine plus or leucine minus conditions. We first verified that PKA signaling is
sensitive to leucine deprivation by demonstrating an increase in Creb (Ser133)
phosphorylation (+200%), which was subsequently reduced (-75%) in the presence of
PKI (Figure 3.4A) regardless of leucine status. Figures 3.4B-E indicate that leucine
deprivation increased IGFBP-1 secretion (+300%) and phosphorylation (pSer101:
+1000%, pSer119: +500%, pSer169: +750%) whether or not PKA was inhibited. These
data suggest that PKA inhibition is unable to attenuate IGFBP-1 phosphorylation
(pSer101, pSer119, pSer169) induced by leucine deprivation, and that PKA does not
modulate hepatic IGFBP-1 secretion phosphorylation under leucine deprivation.
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Figure 3.4. Effects of PKI (5-24) inhibition of PKA on leucine deprivation-induced
IGFBP-1 secretion and phosphorylation.Leucine deprivation induced and PKI
treatment reduced PKA activity, which was not associated with IGFBP-1
phosphorylation in leucine deprivation. Representative western immunoblots of HepG2
cell media indicating A. total and phosphorylated Creb (Ser133) as an indicator of PKA
activity and B-E. IGFBP-1 secretion and phosphorylation at Ser101, Ser119 and Ser169
in control, leucine deprivation, PKI, and leucine deprivation+PKI treatments. Values are
displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; Oneway analysis of variance; Dunnet’s Multiple Comparison Test; n=3. C: Control, 450 μM
leucine. LD: Leucine deprivation, 0 μM leucine. PKI: PKI (5-24) (100 nM), 450 μM
leucine. PKI:LD: PKI (5-24) (100 nM), 0 μM leucine.
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3.3.5 CK2 or PKC kinase inhibition prevents decrease in IGF-I
bioactivity due to IGFBP-1 hyperphosphorylation
We predicted that prevention of leucine deprivation-induced IGFBP-1 phosphorylation
by CK2 or PKC inhibition effectively restores IGF-I bioactivity. To asses this, we
employed our IGF-1 receptor (IGF-1Rβ) autophosphorylation assay in P6 cells to test for
IGF-1R (pTyr1135) autophosphorylation (Figure 3.5), which we used as a measure of
IGF-I bioactivity. We assessed IGF-1Rβ autophopshorylatio (pTyr1135) after exposure
of the P6 cells to conditioned HepG2 cell media from the various inhibitor treatments. P6
cells over-express IGF-1R but do not express IGF-I56. Addition of 25 ng/mL IGF-I only
to P6 cell media (positive control) caused a drastic increase in IGF-1R (pTyr1135)
phosphorylation (a; +2700%) compared to P6 cells incubated in media not supplemented
with IGF-I (negative control) (Figure 3.5), proving that IGF-I addition successfully
induces IGF-1R activity in P6 cells. We considered the IGF-1R autophosphorylation
induced by the addition of IGF-I only (positive control) as 100% activation of the
receptor.
P6 cells were also treated with IGF-I (25 ng/mL) in tandem with conditioned media from
HepG2 cells. Firstly, basal phospho-IGFBP-1 levels (from treatments with 450 µM
leucine and no inhibitors) was used as a control for the comparison of IGF-1R
autophosphorylation to other treatments (lane 3). Next, we used HepG2 conditioned cell
mediafrom cellsthat had been previously deprived of leucine and/or treated with chemical
ihibitors against CK2 (TBB) or PKC (BIS). The varied volumes of conditioned cell
media from each treatment used in the assay were adjusted to contain equal amounts of
total IGFBP-1, ensuring that changes in IGF-1Rβ autophosphorylation in treated P6 cells
are caused by changes in the degree of phosphorylated IGFBP-1.
As expected, basal phospho-IGFBP-1 levels (from treatments with 450 µM leucine)
reduced IGF-1Rβ autophosphorylation (pTyr1135) (b; -45%), regardless of the presence
of inhibitors, compared to when P6 cells were treated with IGF-I only (positive control)
(Figure 3.5). The reduction in IGF-1R autophosphorylation by this treatment served as an
additional positive control for the comparison to pIGFBP-1 levels from other treatments.
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Further, the elevated phospho-IGFBP-1 in leucine-deprived HepG2 cell media almost
completely abolished IGF-1Rβ autophosphorylation (pTyr1135) when no inhibitor was
present in the conditioned cell media (c; -90%) (Figure 3.5). When IGFBP-1
phosphorylation had been prevented by CK2 inhibition (TBB) or PKC inhibition (BIS) in
HepG2 cell and the conditioned cell media incubated with P6 cells, IGF-1R activity in P6
cells remained at basal levels.
Therefore, when either CK2 or PKC was inhibited (with TBB or BIS, respectively),
leucine deprivation was unable to decrease IGF-I bioactivity (Figure 3.5). These data
provide strong evidence that the hyperphosphorylation of IGFBP-1 in leucine deprivation
attenuates IGF-I bioactivity via diminished IGF-1Rβ autophosphorylation (pTyr1135)
(Figure 3.5), and that this effect is prevented by CK2 or PKC inhibition. These findings
are summarized in Table 3.2.
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Figure 3.5. The effects of CK2 and PKC inhibition of IGFBP-1 phosphorylation on
IGF-1R autophosphorylation.CK2 or PKC inhibition mitigates leucine deprivationinduced reduction of IGF-I bioactivity. HepG2 cell media samples were aliquoted to
contain equal concentrations of IGFBP-1 and buffer-exchanged to serum-free P6 media
(DMEM/F12 with pyruvate). Aliquots were then incubated with human recombinant
IGF-I (25 ng/mL) for 2 hours to allow IGFBP-1 binding to IGF-I, followed by a ten
minute exposure to P6 cells to allow induction of IGF-I-mediated IGF-1Rβ
autophosphorylation (Tyr1135). The representative western immunoblot of posttreatment P6 cell lysates (50 μg per lane) assessed for IGF-IRβ autophosphorylation
(Tyr1135) indicates that leucine deprivation-stimulated IGFBP-1 phosphorylation
reduced IGF-1R activation, but was unable to elicit this effect in the presence of BIS or
TBB. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001
versus control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3.
– IGF-I: Negative control, no IGF-I, no IGFBP-1. +IGF-I: Positive control, 25 ng/mL
IGF-I, no IGFBP-1. C:450: Control, 450 μM leucine. C:0: Leucine deprivation, 0 μM
leucine. TBB:450: TBB (1 μM), 450 μM leucine. TBB:0: TBB (1 μM), 0 μM leucine.
BIS:450: Bisindolylmaleimide (7.5 μM), 450 μM leucine. BIS:0: Bisindolylmaleimide
(7.5 μM), 0 μM leucine.
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Table 3.2. Summary of various treatments on P6 cells and consequent changes in IGF1Rβ autophosphorylation (Tyr1135) as a measure of IGF-I bioactivity.
Sample

Treatment

Relative IGF-1R
(Tyr1135)
autophosphorylation

Significance

Baseline IGF-1R
phosphorylation
arbitrarily set at 1
(negative control)
+2700% (positive
control)

p<0.001 vs negative
control

1 -IGF-I

P6 CM only

2 +IGF-I

P6 CM + IGF-I

3 C:450

*HepG2 CM from leucine
plus (450 µM) treatment +
IGF-I

+1500% (positive
control)

p<0.001 vs positive
control (lane 2)

4 C:0

*HepG2 CM from leucine
minus (0 µM) treatment +
IGF-I

+250%

p<0.001 vs C:450
(positive control,
lane 3)

5 TBB:450

*HepG2 CM from leucine
plus (450 µM) and TBB
treatment + IGF-I

+1500%

6 TBB:0

*HepG2 CM from leucine
minus (0 µM) and TBB
treatment + IGF-I

+1200%

7 BIS:450

*HepG2 CM from leucine
plus (450 µM) and BIS
treatment + IGF-I

+1400%

8 BIS:0

*HepG2 CM from leucine
minus (0 µM) and BIS
treatment + IGF-I

+1000%

p<0.001 vs positive
control, n.s. vs C:450
(positive control,
lane 3)
p<0.001 vs positive
control, n.s. vs C:450
(positive control,
lane 3)
p<0.001 vs positive
control, n.s. vs C:450
(positive control,
lane 3)
p<0.001 vs positive
control, n.s. vs C:450
(positive control,
lane 3)

Conclusion

IGF-I induces IGF-1R
autophosphorylation
Basal pIGFBP-1 levels
reduce IGF-1R
autophosphorylation
compared to when
there is no IGFBP-1
present (lane 2)
Leucine deprivation
reduces IGF-1R
autophosphorylation
compare to basal
pIGFBP-1 levels
IGFBP-1
phosphorylation
prevented by TBB did
not cause a further
reduction of IGF-1R
autophosphorylation in
leucine deprivation
IGFBP-1
phosphorylation
prevented by BIS did
not cause a further
reduction of IGF-1R
autophosphorylation in
leucine deprivation

A tabular summary of various treatments on P6 cells and their effect on IGF-1R
autophosphorylation (Tyr1135). Addition of IGF-I stimulated IGF-1R phosphorylation.
All *HepG2 samples contained varied CM volumes that were aliquoted for equal total
IGFBP-1. Leucine deprivation (4) reduced IGF-1R autophosphorylation to a greater
extent than leucine plus samples (3) only when TBB or BIS were not present (6, 8).
CM=conditioned media; *HepG2 CM were buffer-exchanged to P6 cell media prior to
treatment. One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3.
n.s.=not significant.
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3.3.6 Inhibition of CK2 (TBB) or PKC (BIS) signaling attenuates
leucine deprivation-induced CK2 activity
Utilizing a well-established CK2 activity assay75 as previously45, we assessed the effect
of leucine deprivation on CK2 activity in HepG2 cell lysates. Leucine deprivation
increased CK2 activity (+300%) whereas CK2 inhibitor TBB, reduced CK2 activity (50%) despite leucine status (Figure 3.6). As anticipated76, PKC inhibitor (BIS) did not
affect CK2 activity in basal conditions; however, BIS completely obstructed the ability of
leucine deprivation to induce CK2 activity. We thereby demonstrated that leucine
deprivation-mediated induction of CK2 activity is PKC-dependent. These data suggest
that PKC contributes to IGFBP-1 phosphorylation via activating CK2 in leucine
deprivation, implicating the two kinases in a common mechanism regulating IGFBP-1
phosphorylation in leucine deprivation.

Relative CK2 activity
(arbitrary units)

5
4

***

3
2
1

*

*

0
C:450

C:0

BIS:450

BIS:0

TBB:450 TBB:0

Figure 3.6. Effects of various inhibitor treatments on CK2 activity.A CK2 activity
assay demonstrates that leucine deprivation induces CK2 activity, an effect that is
attenuated by BIS. TBB decreases CK2 activity regardless of leucine status. Values are
displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; Oneway analysis of variance; Dunnet’s Multiple Comparison Test; n=3. C:450: Control, 450
μM leucine. C:0: Leucine deprivation, 0 μM leucine. TBB:450: TBB (1 μM), 450 μM
leucine. TBB:0: TBB (1 μM), 0 μM leucine. BIS:450: Bisindolylmaleimide (7.5 μM),
450 μM leucine. BIS:0: Bisindolylmaleimide (7.5 μM), 0 μM leucine.
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3.4

Discussion

In this study, we demonstrate that CK2 and PKC, but not PKA, are involved in mediating
IGFBP-1 phosphorylation (Ser101, Ser119, Ser169) caused by leucine deprivation in
HepG2 cells. Inhibition of CK2 or PKC attenuated IGFBP-1 phosphorylation (pSer101,
pSer119, pSer169) elicited by leucine deprivation without affecting the induction of total
IGFBP-1. Our findings are consistent with our hypothesis that CK2 and PKC modulate
hepatic IGFBP-1 phosphorylation in response to leucine deprivation, but contradict our
prediction that PKA is also implicated in this mechanism. Importantly, we demonstrate
that inhibition of CK2 or PKC prevented leucine deprivation-induced decreases in IGF-I
bioactivity via our established40 IGF-1R autophosphorylation assay, illustrating roles for
both CK2 and PKC in modulating IGF-I bioactivity under amino acid (leucine) restriction
in vitro. Importantly, we demonstrated that PKC inhibition attenuated leucine
deprivation-stimulated CK2 activity without affecting CK2 activity in basal conditions,
suggesting that PKC likely modulates IGFBP-1 phosphorylation by diminishing CK2
activity in leucine deprivation (Figure 3.6, bar 2 vs. bar 4).
This study is the first, to our knowledge, to demonstrate roles for both CK2 and PKC in
modulating fetal hepatic IGFBP-1 phosphorylation in response to leucine deprivation.
Since the majority of IGF exists in circulation bound to one of the IGFBPs77, fluctuations
in the relatively low amount of free circulating IGF-I can have dramatic effects on its
capacity to transduce cell growth and proliferation. As the predominant circulating fetal
IGFBP during gestation28, the ability of IGFBP-1 to modulate IGF-I bioavailability is
critical to fetal growth. In utero amino acid deprivation is a hallmark of FGR5,78, and
acutely influences IGFBP-1 phosphorylation46 and IGF-I bioavailability17,79. IGFBP-1
phosphorylation is increased in growth-restricted fetuses44, an occurrence specific to
humans44,80. Reports from our laboratory have demonstrated that human FGR fetuses
display elevated pIGFBP-1 (pSer101, pSer119 and pSer169) in cord serum45 and in
amniotic fluid69. Since IGFBP-1 hyperphosphorylation is correlated with reduced IGF-I
bioactivity in vitro and in vivo, such as determined through an IGF-1R phosphorylation
assay previously in our lab71, the kinases and phosphatases which phosphorylate and de-
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phosphorylate IGFBP-1, respectively, in leucine deprivation are likely critical in
modulating IGF-I bioavailability, and potentially contribute to FGR pathogenesis in vivo.
In previous studies, CK247,49 and PKA47 were proposed to phosphorylate IGFBP-1 when
the kinases were directly incubated with the purified substrate. However, whether these
kinases are mechanistically linked to IGFBP-1 phosphorylation within live cells cannot
be extrapolated from these studies, since other kinases may be elicited under various
stimuli, such as nutritional stress, to be functionally relevant and impinge on IGFBP-1
phosphorylation in these circumstances. By inhibiting our kinases of interest and
measuring IGFBP-1 phosphorylation in conditioned cell media from the same cells, we
identify direct links between these kinases and IGFBP-1 phosphorylation in live cells.
We recently illustrated that CK2 is mechanistically linked to IGFBP-1 phosphorylation at
Ser101, Ser119 and Ser169 by demonstrating decreased phosphorylated IGFBP-1 in
conditioned cell media from HepG2 cells treated with TBB (CK2 inhibitor)45. Using a
similar in vitro approach in the current study, we demonstrate that CK2 is a key
mechanistic link between leucine deprivation and IGFBP-1 phosphorylation. Together
with our previous45 observations that CK2 activity is elevated in growth-restricted
baboon hepatocytes in vivo, our findings implicate CK2 as the likely kinase modulating
IGFBP-1 phosphorylation under amino acid deprivation in FGR. PKA, on the other hand,
has not been mechanistically linked to IGFBP-1 phosphorylation in live cells.
Additionally, PKC has not been studied for its explicit role in regulating IGFBP-1
phosphorylation despite possessing consensus sequence sites for multiple residues on the
IGFBP-1 molecule (Table 3.1) and its altered expression in FGR placentas68. In addition
to Ser101, Ser119 and Ser169 which have been demonstrated by our team to be
hyperphosphorylated in FGR42,45,69, phosphorylation of IGFBP-1 at additional sites such
as Ser95 and Ser98 which have been previously identified by us and by others46, 70,71 may
be functionally relevant both independently and through synergistic interactions with
Ser101, Ser119 and Ser169 in FGR.
The three phosphorylated residues in IGFBP-1 (Ser101, Ser119, Ser169) in FGR are were
identified by LC-MS/MS previously in our lab81, and are proximal to acidic amino acids

147

(Table 3.1) adjacent to structured IGF-I-binding (Ser101, Ser169) and in unstructured
regulatory (Ser119) regions on the IGFBP-1 molecule48, making them conducive to direct
phosphorylation by CK250,82. In particular, Ser119 and Ser169 contain exact consensus
sequences for direct phosphorylation by CK2 (Table 3.1). Leucine deprivation induces
CK2 activity, which likely leads to the kinase directly phosphorylating IGFBP-1 at
Ser101, Ser119 and Ser169 in HepG2 cells, however, future CK2:IGFBP-1binding
studies would clarify whether IGFBP-1 is a true CK2 substrate. On the other hand,
IGFBP-1 is less likely to be directly phosphorylated by PKC at Ser101, Ser119 and
Ser169, since direct phosphorylation by this kinase requires the proximity of basic amino
acid residues to the phospho-acceptor site (consensus site: pS/T-X-R/K)82 (Table 3.1). It
is possible that PKC regulates IGFBP-1 phosphorylation via upstream modulation of
CK2 activity, since it was demonstrated here that BIS, a PKC-specific inhibitor, prevents
CK2 induction by leucine deprivation without affecting CK2 activity in basal conditions,
in concurrence with previous literature reports76(Figure 3.6). It is also possible that PKC
phosphorylates IGFBP-1 at discrete sites, such as pT50AR and pS58CR (Table 3.1), with
functional effects on IGFBP-1 activity, which can be investigated in future studies. This
finding unequivocally links CK2 and PKC signaling in a common signaling network
specifically in leucine deprivation. It is therefore likely that PKC-mediated IGFBP-1
phosphorylation occurs via downstream interactions with CK2 in leucine deprivation.
In our previous reports, phosphorylation at the various Ser residues in IGFB-1 elicited
variable affects on IGFBP-1 affinity for IGF-I46, and mutations which rendered any of the
three sites un-phosphorylatable potentiated IGF-I bioactivity, as determined via IGF-1R
autophosphorylation in HepG2 cells71. However, the exact conformational changes on the
IGFBP-1 molecule elicited by phosphorylation at Ser101, Ser119 and Ser169 that affect
its affinity for IGF-I are unknown. It is likely that phosphorylation at Ser101, Ser119 and
Ser169 function concomitantly to induce conformational changes which increase IGFBP1 affinity for IGF-I. To assess this hypothesis, future structural studies on CK2/IGFBP-1
binding will be valuable. Overall PKC activity is reduced and the expression patterns of
the various isoforms are altered in cellular nutritional stress59,60,83-85. The isoform-specific
distribution and functions of PKC are not well understood. Unlike the cPKCs, nPKCs do
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not contain the C2 regulatory domain; however, the functional relevance of this structural
difference has not been established65. Comparatively, aPKCs lack the structural
components of cPKCs and nPKCs that are required for their activation by diacylglycerols
and phorbal esters, suggesting atypical intracellular regulation of the aPKCs65. Assaying
the down-regulated expression of all PKCs silenced by siRNA against pan-PKC was not
realistic in this study. Therefore, we verified efficient PKC knockdown using the
expression levels of nPKCδ and nPKCε as representatives as measures of the efficiency
of pan-PKC siRNA, as these isotypes have been established to be predominantly
expressed in HepG2 cells and have demonstrated to be sensitive to nutritional status61,74.
Down-regulation of overall PKC activity has been linked to total IGFBP-1 mRNA and
protein expression64,86,87, although its effects on post-translational regulation of IGFBP-1
have not been classified. We report for the first time that PKC is involved in modulating
IGFBP-1 phosphorylation in leucine deprivation, and that PKC function is necessary for
leucine deprivation to induce CK2 activity in vitro. The placentas of rats with
glucocorticoid-induced FGR display an altered pattern of PKC isoform expression67. This
suggests that PKC signaling is dynamically implicated in FGR although the exact role of
PKC function is FGR has not been established. If PKC modulates CK2 activity in
growth-restricting conditions in vivo, it is possible that PKC and CK2 are mechanistically
linked to IGFBP-1 phosphorylation in FGR.
Although PKA activity is associated with IGFBP-1 phosphorylation in endometrial
stromal cells44, The inability of PKA inhibition to effectively prevent IGFBP-1
phosphorylation in HepG2 cells confers specificity to CK2 and PKC in the mediation47 of
leucine deprivation-stimulated phosphorylation of hepatic IGFBP-1. Therefore, CK2 and
PKC, but not PKA, may be critical in modulating IGFBP-1 phosphorylation in the fetal
compartment in FGR. Our results indicate that CK2 and PKC modulate leucine
deprivation-induced IGFBP-1 hyperphosphorylation at all three sites (pSer101, pSer119
and pSer169). Whether phosphorylation of Ser101, Ser119 and Ser169 is independently
regulated or a collection of co-dependent phosphorylation events is a topic for future
exploration. Similar to our previous results (Chapter 2), we have demonstrated here that
leucine deprivation most potently stimulates IGFBP-1 phosphorylation at Ser101 and
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Ser169. During pregnancy, placental alkaline phosphatase de-phosphorylates IGFBP-1 in
order to increase IGF-I bioavailability88. Therefore, de-phosphorylation of IGFBP-1 may
be an additional mechanism by which cells modulate IGF-I bioavailability in FGR.
In conclusion, our present study identifies protein kinases CK2 and PKC as critical
mediators of IGFBP-1 phosphorylation under nutrient (leucine) deprivation in vitro.
Taken together with our previous studies45, we speculate that CK2 is the key modulator
of IGFBP-1 phosphorylation in response to amino acid restriction in FGR. Our novel
demonstration that PKC is also linked to IGFBP-1 phosphorylation in leucine deprivation
in vitro, and that PKC inhibition attenuates leucine deprivation-induced CK2 activity,
illustrates a potential role for PKC signaling in a combined signaling mechanism with
CK2 in modulating IGF-I bioavailability in FGR. Since leucine deprivation-induced
decreases in IGF-I bioactivity are prevented by inhibition of CK2 or PKC, our findings
bare physiological relevance. In vivo, the targeted inhibition of CK2 or PKC activity to
circumvent amino acid deprivation-induced loss of IGF-I bioactivity may be valuable. By
linking CK2 and PKC in a common mechanism modulating IGFBP-1 phosphorylation in
leucine deprivation in vitro, we are one step closer to unraveling the molecular
mechanisms underlying in utero FGR.
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Summary and Conclusions
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4.1 Summary of Findings
Amino acid (leucine) deprivation stimulated IGFBP-1 phosphorylation at Ser101, Ser119
and Ser169 in all experiments conducted in HepG2 cells (Chapters 2 and 3), as
anticipated from previous reports1. However, the molecular mechanisms modulating
hepatic IGFBP-1 phosphorylation in leucine deprivation had previously remained elusive.
Through selective manipulation of the mTOR and AAR signaling cascades (Chapter 2) as
well as protein kinases CK2, PKC and PKA (Chapter 3) in leucine deprived conditions,
we have successfully shed light on the signaling pathways linking reduced leucine supply
to stimulated IGFBP-1 phosphorylation in vitro. These findings contribute insight to how
nutrient deprivation leads to decreased fetal growth, by way of increased IGFBP-1
phosphorylation, in FGR.
In Chapter 2, we show that manipulation of hepatic amino acid-sensing mTOR and AAR
pathways variably affected the ability of leucine deprivation to elicit IGFBP-1
phosphorylation. Based on previous findings by our group that mTOR modulates IGFBP1 phosphorylation in baboon fetal hepatocytes from a primate model for FGR2, and
considering that mTOR is critically involved in placental nutrient sensing and is highly
sensitive to amino acid status3, we had initially hypothesized that mTORC1+C2 signaling
was the primary mechanism by which IGFBP-1 phosphorylation is induced under leucine
deprivation. We demonstrated that the fetal hepatic (HepG2) mTOR pathway was indeed
down-regulated by leucine restriction, as expected; however, this was linked to only a
partial induction of the IGFBP-1 phosphorylation otherwise caused by leucine
deprivation. We concluded that mTOR signaling only partially modulated IGFBP-1
phosphorylation under leucine deprivation because although leucine deprivation reduces
mTORC1+C2 activity, it stimulates IGFBP-1 phosphorylation to a greater extent than
mTORC1+C2 inhibition by itself. Importantly, although leucine deprivation and mTOR
inhibition both separately induced IGFBP-1 phosphorylation to different extents, their
effects were not cumulative when combined. This observation suggested that mTORmediated induction of IGFBP-1 phosphorylation occurred in a common mechanism with
leucine deprivation.
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We verified our findings via constitutive activation of mTORC1+C2 by DEPTOR
silencing, which resulted in the inability of leucine deprivation to inhibit mTORC1+C2
activity. This prevented leucine deprivation from eliciting IGFBP-1 secretion; however,
IGFBP-1 phosphorylation (Ser101, Ser119 and Ser169) was nevertheless induced by
leucine deprivation. These observations confirmed that although mTOR is a key mediator
of IGFBP-1 secretion under leucine restriction, there was a need to explore additional
cellular mechanisms that the cell may rely on to induce IGFBP-1 phosphorylation under
nutritional stress.
The observation that alternate mechanisms in addition to mTOR are elicited by leucine
deprivation to induce IGFBP-1 phosphorylation prompted the investigation of the AAR.
The AAR is a specific cellular response to restricted amino acid availability4, and is
known to be systemically involved in mediating the stress response to nutritional
insufficiency to down-regulate overall cell growth and proliferation, making it a likely
candidate for modulation of IGFBP-1 phosphorylation under leucine deprivation. Due to
the commercial unavailability of specific pharmacological inhibitors against the AAR,
our primary investigation of the AAR relied on its cross-talk with MEK/ERK signaling.
MEK/ERK signaling is necessary for the propagation of the AAR by GCN25, the
exclusive nutrient sensor to the AAR4. We chemically inhibited MEK/ERK signaling
with pharmacological inhibitor U0126 in order to wholly mitigate the activity of this
specific MKK/MAPK arm of the MKKK signaling cascade6. We successfully
demonstrated that U0126 was able to attenuate the AAR downstream of GCN2 and that
this fully obstructed the ability of leucine deprivation to induce IGFBP-1 phosphorylation
(Ser101, Ser119 and Ser169). We confirmed and validated these findings with ERK1/2
siRNA, which was conducted separately and combined with GCN2 siRNA in order to
conclusively determine whether leucine deprivation-mediated IGFBP-1 phosphorylation
occurs via the AAR. This led to our experiment where we silenced ERK1/2 and GCN2 in
tandem, and proved that the ability of MEK/ERK to modulate IGFBP-1 phosphorylation
under leucine deprivation is, in fact, due to its participation in the AAR.
In Chapter 3, we surveyed various kinases speculated to modulate IGFBP-1
phosphorylation for their ability to mediate IGFBP-1 phosphorylation in leucine

161

deprivation.The molecular mechanisms regulating IGFBP-1 phosphorylation, especially
under nutrient depletion, are largely unexplored in the literature. CK2, PKC, and PKA
have been suggested to phosphorylate IGFBP-17. Specifically, our sites of interest
(pSer101, pSer119, pSer169) are likely to be directly phosphorylated by CK27 due to
surrounding acidic amino acid residues to the phospho-acceptor sites. Recent success by
our team in demonstrating that that CK2 modulates IGFBP-1 phosphorylation in HepG2
cells and primary baboon hepatocytes2 motivated this investigation. We presupposed that
inhibiting CK2, but not PKC or PKA, in leucine deprivation would attenuate leucine
deprivation-induced IGFBP-1 phosphorylation and that this would extend our previous2
observations that CK2 is the key kinase involved in IGFBP-1 phosphorylation in nutrient
restricted conditions. First, using pharmacological inhibitor TBB against CK2, we
demonstrated that CK2 inhibition obstructed the ability of leucine deprivation to induce
IGFBP-1 phosphorylation. In these same samples, we verified that TBB reduced CK2
activity regardless of leucine status, which otherwise stimulated CK2 activity. The ability
of TBB to attenuate IGFBP-1 phosphorylation was independent of overall IGFBP-1
secretion, since total IGFBP-1 output was elevated in leucine deprivation despite the
presence of TBB. Follow-up siRNA experiments against CK2(α+α’+β) proved that CK2
is essential for leucine deprivation to stimulate IGFBP-1 phosphorylation at all three sites
(Ser101, Ser119 and Ser169).
Chemical inhibition of PKA was unable to alter IGFBP-1 phosphorylation in HepG2 cells
regardless of leucine status. However, PKC inhibition or silencing was demonstrated
here, for the first time, to not only modulate hepatic IGFBP-1 phosphorylation but to also
coordinate this event under leucine deprivation (Chapter 3). Unlikely to be a direct kinase
for the phosphorylation of IGFBP-1 at our sites of interest (pSer101, pSer119 and
pSer169)7, we assessed whether the ability of PKC to modulate IGFBP-1 phosphorylation
was due to mechanistic cross-talk with CK2. Our CK2 activity assay verified that PKC
inhibition with BIS prevented the ability of leucine deprivation to induce CK2 activity,
although BIS did not affect CK2 activity under basal conditions, as expected8. The
finding that CK2 likely phosphorylates IGFBP-1 downstream of PKC in leucine
deprivation is the first report of potential interactions between PKC and CK2 in HepG2
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cells. Finally, to attribute functional relevance to our findings, we used our previously
established9 IGF-1R autophosphorylation assay to demonstrate that changes in phosphoIGFBP-1 content in conditioned media variably affected IGF-I bioactivity.
Table 4.1. Summary of various treatments on IGFBP-1 secretion and
phosphorylation.
Treatment

Effect on
intracellular
signaling

Figure
Reference

IGFBP-1
Secretion

IGFBP-1
Phosphorylation

Figure
reference

mTOR pathway
Rapamycin
Raptor+Rictor
siRNA
DEPTOR
siRNA
AAR pathway

mTORC1+C2
inhibition
mTORC1+C2
activation

U0126
ERK siRNA
GCN2 siRNA

AAR pathway
inhibition

ERK+GCN2
siRNA
Kinase Treatments
TBB
CK2α+α’+β
siRNA

PKI (5-24)

Figures 2.1C-F
No significant
effect

Figures
2.2A-B

Figures
2.3A-D
Figures
2.4A-C

Figures 2.2C-F

Figures 2.3E-H
Figures 2.4D-G

Figures
2.5A-B

Figures 2.5C-F

Figure 3.7

Figures 3.1A-D

CK2 inhibition
N/A

BIS
pan-PKC
siRNA

Figures
2.1A-B

N/A

No
significan
t effect

Figures 3.2A-D
Figures 3.3A-D

PKC inhibition
N/A
PKA inhibition Figure 3.5A

Figures 3.4A-D
No significant effect

Figures 3.5B-E

mTOR signaling modulates IGFBP-1 secretion but not phosphorylation caused by leucine
deprivation. The AAR regulates both IGFBP-1 secretion and phosphorylation in leucine
deprivation. CK2 and PKC are key kinases involved in modulating IGFBP-1
phosphorylation in leucine deprivation.
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Loading controls for secretory proteins
A recurring concern in this study, as well as in the literature, is a lack of a consistent
loading control for western blots of secretory proteins in conditioned cell media. β-actin
served as a reliable loading control for western blots of whole cell lysates throughout this
study, however, treatment-dependent fluctuations in IGFBP-1 secretion and
phosphorylation were determined with western blots using conditioned media from
HepG2 cell cultures, which have not been previously demonstrated to secrete any protein
in a consistent quantity irrespective of treatments. Reversible stains for total protein, such
as Ponceau stains, are not well accepted tools for the detection of equal loading between
lanes due to their lack of sensitivity and specificity of the bands being stained10,11.
Proteins that are enriched in conditioned media compared to lysatesamples are specific to
cell-type and may be used as quality controls for western blots12. To improve the validity
of our western blots, we speculated as to which HepG2 secreted protein could serve as a
reliable loading control. Based on the HepG2 secretome13, which indicates that
fibrinogen is synthesized and secreted in high quantities by HepG2 cells13-15 we evaluated
whether fibrinogen could serve as an effective loading control for western blots of our
conditioned HepG2 cell media.
Due to the observation that fibrinogen secretion remained consistent among treatments
regardless of the presence of inhibitor, fibrinogen output served as a valuable tool to
ensure equal loading among lanes (Appendix D; Supplementary Figure 4.4). A
representative western blot of conditioned media from leucine plus, leucine minus, and
combined leucine plus/minus treatments with the various inhibitors that affect IGFBP-1
phosphorylation used in this study (TBB, BIS, PKI, U0126) was probed with primary
antibody against pSer101 (IGFBP-1), total IGFBP-1, and fibrinogen. Fibrinogen
secretion remained consistent among all treatments irrespective of inhibitor-induced
fluctuations in IGFBP-1 secretion or phosphorylation. Therefore, we verified that the
differences in IGFBP-1 secretion and phosphorylation elicited by inhibitor treatments are
independent of total loaded conditioned media (Appendix D).
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Figure 4.2. Schematic of established mechanistic links between leucine deprivation and total and
phospho-IGFBP-1.

4.2

Extensions, Perspectives and Significance

The bioinhibitory capacity of IGFBP-1 on IGF-I is widely acknowledged. For example,
IGFBP-1 impedes IGF-I-dependent amino acid transport16 and DNA synthesis17,18. The
capacity of phosphorylated IGFBP-1to bind and sequester IGF-I is greater than that of the
un-phosphorylated isoform19,20, suggesting that IGFBP-1 hyperphosphorylation bears
significant functional relevance in the context of IGF-I bioactivity. The extent to which
leucine deprivation induced IGFBP-1 phosphorylation (up to 2500%) in this study far
superseded the extent to which leucine deprivation induced overall IGFBP-1 secretion
(maximum observed 500% induction), demonstrating the impact leucine restriction has
on mitigating IGF-I bioactivity through regulating its binding protein. This observation
justifies why the identification of the signaling mechanisms which link leucine
deprivation to IGFBP-1 hyper-phosphorylation is absolutely critical in understanding the
regulation of IGF-I bioactivity under amino acid restriction.
The finding that mTOR mediates IGFBP-1 secretion but is only partially responsible for
IGFBP-1 phosphorylation in leucine deprivation, combined with the observation that
CK2 or PKC inhibition prevents IGFBP-1 phosphorylation without affecting its overall
secretion in leucine deprivation, demonstrates that the molecular mechanisms elicited by
leucine deprivation to regulate IGFBP-1 phosphorylation are independent of those which
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modulate its total secretion. This clear illustration of a bipartite mode of regulation for
IGFBP-1 secretion compared to its phosphorylation under leucine restriction suggests
that IGFBP-1 phosphorylation occurs as an independent cellular response to nutritional
stress. This finding has functional relevance in FGR, which our team has
previouslyassociated with hyperphosphorylated IGFBP-1 in both maternal22 and fetal2
compartments. Linking CK2 and PKC – which were identified in this study to modulate
IGFBP-1 phosphorylation in leucine deprivation – to the AAR will be valuable in
elucidating the specific cellular response toamino acid deprivation to phosphorylate
IGFBP-1in vitro. Identification of the signaling mechanisms modulating IGFBP-1
phosphorylation in this study lays the groundwork forfuture investigation on the roles of
these specific signaling mechanisms in modulating IGFBP-1 phosphorylation in amino
acid deprivationin vivo. If IGFBP-1 phosphorylation is modulated in vivo by the same
molecular components identified in this study, these pathways may serve as candidatesfor
future studies aimed at identifying targets for manipulation to offset IGFBP-1
phosphorylation in FGR.
The ultimate goal of the AAR is to arrest anabolic activity in favour of energy
preservation upon amino acid restriction23. Induced ATF4 expression is not exclusive to
amino acid deprivation – in fact, ATF4 is a conjunction point for multiple stressresponsive pathways such as the Unfolded Protein Response (UPR) and elicits stressorspecific gene programs. The gene expression profiles elicited by ATF4 from the AAR
(via GCN2 sensing) and UPR are mutually exclusive, although there is a significant
degree of overlap23. The mechanism by which ATF4 discriminates between multiple
upstream signals is not understood. Thus, our rationale for silencing GCN2 rather than
eIF2α or ATF4 is the specificity of GCN2 to the AAR. Although the AAR was
demonstrated to be indispensable in modulating IGFBP-1 phosphorylation in leucinedeprived HepG2 cells (Chapter 2), it is likely that the AAR coordinates withadditional
signaling mechanisms down-stream, including mTOR, in order to transduce its effects. It
is possible that the AAR and mTOR signaling pathways impinge on each other
downstream to modulate leucine deprivation-induced IGFBP-1 secretion and
phosphorylation in a common mechanism. Indeed, the mTOR and AAR pathways exhibit
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a knownconvergence point: DNA damage response 1 (REDD1). GCN2-mediated eiF2α
phosphorylation induces REDD124, an essential component of the mTOR signaling
cascade25, thereby coordinating the two pathwaysdownstream. Another mode of
convergence may, in fact, be CK2, which has shown to interact with ATF426,27, possibly
linking the nutrient-responsive kinase with the AAR. Future studies to elucidate the
interaction between the AAR and mTOR pathways in vitro will provide further
insight into the mechanisms modulating IGFBP-1 phosphorylation.
Previous work by our lab2 has linked mTOR signaling and CK2 kinase activity in the
regulation of hepatic IGFBP-1 phosphorylation. The studies presented here demonstrate
that additional mechanisms to mTOR and CK2 are implicated in IGFBP-1
phosphorylation in amino acid deprivation. The cellular response to nutritional stress is
dynamic. For instance, the AAR (Chapter 2) and PKC (Chapter 3) were discovered, for
the first time, to play pivotal roles in IGFBP-1 phosphorylation in leucine-restricted
conditions in vitro. The ability of PKC to mediate IGFBP-1 phosphorylation at Ser101,
Ser119, and Ser169 while simultaneously modulating CK2 activity in leucine deprivation
illustrates a novel role for PKC in modulating IGFBP-1 phosphorylation. Together, our
findings demonstrate that the regulation of IGF-I bioactivity via phosphorylation of its
binding protein is dynamic and influenced by multiple signaling pathways.
Combined with previous in vitro studies demonstrating that CK2 directly phosphorylates
IGFBP-1 in HepG2 cells28 and past work in our lab which linked CK2 activity with
IGFBP-1 phosphorylation in fetal hepatocytes from MNR baboon mothers2, our findings
suggest that CK2 is the key kinase responsible for directly phosphorylating fetal hepatic
IGFBP-1 in amino acid deprivation. The contribution of PKC to IGFBP-1
phosphorylation had not been previously reported, although its role in regulating IGFBP1 at the transcriptional and translational level has been studied32-34. PKC does not contain
consensus sequence sites for phosphorylation at IGFBP-1 at Ser101, Ser119 and Ser169,
although it does contain consensus sequence sites for IGFBP-1 phosphorylation at Ser50
and Ser58. It is possible that PKC-mediated phosphorylation at these discrete sites
contributes to modulating IGFBP-1 affinity for IGF-I independently or through
synergistic effects with Ser101, Ser119 and Ser169. Future studies employing mass
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spectrometry will be valuable in assessing the phosphorylation of IGFBP-1 at these sites
in leucine deprivation. Considering the greater likelihood that IGFBP-1 at Ser101, Ser119
and Ser169 is phosphorylated by CK2 due to surrounding amino acid residues on IGFBP1, our finding that PKC modulates IGFBP-1 phosphorylation at these sites in leucine
deprivation warranted exploration of the interaction between PKC and CK2 in leucine
deprivation. Our CK2 activity assay which demonstrated that PKC inhibition attenuated
leucine deprivation-induced CK2 activitysuggested that the effect of PKC on IGFBP-1
phosphorylation (Ser101, Ser119 and Ser169) is likely due to an upstream link in a
common signaling mechanism with CK2 in leucine deprivation. PKC and CK2are both
implicated downstream of mTOR signaling, however, whether PKC directly modulates
CK2 or whether other molecular components are implicated is not known. It is possible
that CK2 activity is regulated downstream of PKC in leucine deprivation, and is an
attractive area for future in vitro research in HepG2 cells.
To reduce overall PKC signaling, we used pharmacological inhibitor BIS which inhibits
all 12 PKC isoforms31or pan-PKC siRNA.It is possible that specific PKC isoforms, rather
than overall PKC activity, are specifically implicated in CK2-mediated IGFBP-1
phosphorylation. Future in vitro can be conducted in HepG2 cells to assess isoformspecific roles of PKC in modulating IGFBP-1 in leucine deprivation using targeted
RNAiagainst specific PKC isoforms.
The mechanism by which pSer101, pSer119 and pSer169 elicit conformational
changes on the IGFBP-1 molecule to contribute to increased affinity of IGFBP-1 for
IGF-I is presently unknown. The complete 3D structure of IGFBP-1 has yet to be
resolved35. Ser101 and Ser169 are proximal to structured, IGF-I binding regions in
the quaternary protein structure while Ser119 is contained within the protein’s
mobile linker region 45. Covalent modifications at these sites likely cause
conformational changes that influence IGFBP-1 interactions with IGF-I. It is notable
that IGFBP-1 phosphorylation protects it from proteolytic cleavage 36,thus increasing
the compound’s half-life. The induction of phosphorylation at Ser101, Ser119 and
Ser169 in leucine deprivation suggests that the collective contribution of
phosphorylation at each of the three sites is essential in modulating IGF -I
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bioavailability compared to phosphorylation at any site alone. Previously published
data from our lab demonstrated that IGFBP-1 individually mutated at any of the three
studied phospho-acceptor sites (Ser101Ala, Ser119Ala and Ser169Ala) affect the
ability of IGFBP-1 to modulate IGF-I bioavailability9, validating the functional
relevance of phosphorylation at these three sites. The existence of multiple
phosphorylated IGFBP-1 residues highlights the importance of potential synergistic
effects between the various phosphorylated residues. The observation that
phosphorylation at Ser101, Ser119 and Ser169 was prone to inhibition by all
biological and chemical treatments in this study suggests that the regulation of
phosphorylation at each of the residues is implicated in a common signaling
mechanism. It is ascertainable that phosphorylation of a particular phospho-site can
lead, either directly or indirectly, to the phosphorylation of the other residues.
Finally, future molecular modeling studies of phosphorylated IGFBP-1 may be
valuable to demonstrate how the individual and combined phosphorylation of
Ser101, Ser119 and Ser169 elicits conformational changes to IGFBP-1 structure to
directly contribute to IGF-I affinity.
Significance and Future Directions
By elucidating the relative contributions of the mTOR and AAR signaling pathways and
CK2, PKC, and PKA kinases in regulating IGFBP-1 phosphorylation under leucine
deprivation, this study has contributed vital pieces to the understanding of IGFBP-1
phosphorylation in vitro. Our findings provide justification for future investigation into
the mechanistic links between the various molecular components shown here to modulate
IGFBP-1 phosphorylation in leucine deprivation. For example, it is unknown whether
PKC and CK2 mediated IGFBP-1 phosphorylation is coordinated downstream of the
AAR in a common signaling mechanism. It is also yet to be determined the precise
mechanism by which PKC modulates IGFBP-1 phosphorylation at three sites for which it
does not share consensus sequences (Ser101, Ser119, Ser169). PKC may modulate
IGFBP-1 phosphorylation through synergistic effects of phosphorylation at descrete
residues or via direct modulation of CK2 activity. The next step would be to replicate
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these findings in in vivo models, such as our lab’s established primary fetal baboon
hepatocytes, in order to further attribute functional significance to our findings.
Due to the variety of factors which contribute to fetal development43,44, the appropriate
functioning of intracellular signaling mechanisms which modulate fetal growth is
paramount to healthy fetal development. Several intracellular signaling pathways impinge
on one another, and abrogation in any component of this molecular web can lead to
altered fetal growth. Decoding the signaling pathways involved in IGFBP-1
phosphorylation in amino acid-restricted conditions in vitro will provide clues as to the
signaling mechanisms implicated in the pathogenesis of FGR in utero. The idea that adult
morbidity has “developmental origins” has strong implications on public health and
disease prevention37, and we hope that the findings from this study will set the
groundwork for future studies aimed at elucidating the pathogenesis of FGR.
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Appendix A

Supplementary Figure 2. 1. Efficiency of raptor+rictor and DEPTOR silencing. A
representative immunoblot of HepG2 cell lysates (50 μg per lane) assayed for raptor,
rictor, or DEPTOR expression following siRNA silencing. A-B. Raptor+rictor silencing
significantly reduced the expression of raptor (-45-50%) and rictor (-50%) regardless of
leucine status, but did not affect DEPTOR expression. C. DEPTOR expression was
reduced (-50%) in HepG2 cells treated with siRNA against DEPTOR, but not against
raptor+rictor. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p <
0.001 versus control; One-way analysis of variance;
Dunnet’s Multiple Comparison Test; n=3. Sc: Scrambled siRNA, 450 μM leucine.
Sc:LD: Scrambled siRNA, 0 μM leucine. RR: Raptor+Rictor siRNA, 450 μM leucine.
RR:LD: Raptor+Rictor siRNA, 0 μM leucine. D: DEPTOR siRNA, 450 μM leucine.
D:LD: DEPTOR siRNA, 0 μM leucine.
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Cell Vitality
(arbitrary units)
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Supplementary Figure 2. 2. HepG2 cell vitality after treatment with U0126 (10 μM)
for 24 hours. A graphical representation of cell vitality between leucine plus or leucine
deprived with or without U0126 treatments. A Trypan Blue exclusion assay was
performed to assess cell viability, presented here as a percentage of live cells/total cells
normalized to viability in control samples (leucine plus, no inhibitor). Leucine
deprivation and the U0126 inhibitor did not separately or together significantly affect cell
survival. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001
versus control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3.
C: Control, 450 μM leucine. LD: Leucine deprivation, 0 μM leucine. U: U0126 (10 μM),
450 μM leucine. U:LD: U0126 (10 μM), 0 μM leucine.
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Supplementary Figure 2. 3. Efficiency of ERK silencing. A representative western
immunoblot of total ERK expression in HepG2 cell lysates silenced with scrambled or
ERK siRNA with or without leucine deprivation. Equal protein loading (50 μg per lane)
was conducted. Total ERK expression was reduced (-40%) in cells treated with ERK
siRNA, and remained unaffected in cells treated with scrambled siRNA. Values are
displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; Oneway analysis of variance; Dunnet’s Multiple Comparison Test; n=3. Sc: Scrambled
siRNA, 450 μM leucine. Sc:LD: Scrambled siRNA, 0 μM leucine. ERK: ERK1/2 siRNA,
450 μM leucine. ERK:LD: ERK1/2 siRNA, 0 μM leucine.
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Supplementary Figure 2. 4. Efficiency of GCN2, ERK, and GCN+ERK silencing.
Representative immunoblots of HepG2 cell lysates (50 μg per lane) assayed for GCN2 or
ERK expression following siRNA silencing. A. GCN2 silencing significantly reduced the
expression of GCN2 (-50%) regardless of leucine status when GCN2 was silenced alone
or in combination with ERK, and was unaffected when only ERK was silenced. B. ERK
expression was reduced (-40%) in HepG2 cells treated with siRNA against ERK whether
or not GCN2 was also silenced. GCN2 silencing had no significant effect on ERK
expression and this effect was consistent in leucine plus or leucine deprived samples.
Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus
control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3. Sc:
Scrambled siRNA, 450 μM leucine. Sc:LD: Scrambled siRNA, 0 μM leucine. GCN2:
GCN2 siRNA, 450 μM leucine. GCN2:LD: GCN2 siRNA, 0 μM leucine. ERK: ERK1/2
siRNA, 450 μM leucine. ERK:LD: ERK1/2 siRNA, 0 μM leucine. GCN2:ERK:
GCN2+ERK1/2 siRNA, 450 μM leucine. GCN2:ERK:LD: GCN2+ERK1/2 siRNA, 0 μM
leucine.
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Cell Vitality
(arbitrary units)
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Supplementary Figure 2. 5. HepG2 cell vitality after treatment with TBB (1 μM) for
24 hours.A graphical representation of cell vitality between leucine plus or leucine
deprived with or without TBB treatments. A Trypan Blue exclusion assay was performed
to assess cell viability, presented here as a percentage of live cells/total cells normalized
to viability in control samples (leucine plus, no inhibitor). Leucine deprivation and the
TBB inhibitor did not separately or together significantly affect cell survival. Values are
displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; Oneway analysis of variance; Dunnet’s Multiple Comparison Test; n=3. C: Control, 450 μM
leucine. LD: Leucine deprivation, 0 μM leucine. TBB: TBB (1 μM), 450 μM leucine.
TBB:LD: TBB (1 μM), 0 μM leucine.
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Supplementary Table 2. 1. Comprehensive overview of assayed proteins.
Fraction Component
Phosphosite(s)
Indicates
assayed tested
AAR pathway
GCN2
Thr898
eIF2α
Phosphorylation Ser51
HepG2
AAR pathway activation
cell
lysate
ERK
Thr202/Tyr204
ATF4
Expression
N/A
mTOR pathway
Raptor
siRNA silencing
Rictor
Expression
N/A
efficiency
HepG2
DEPTOR
cell lysate
p70-S6K
Thr389
mTORC1 activity
Phosphorylation
Akt
Ser473
mTORC2 activity
IGFBP-1 (total and phosphorylated)
HepG2
Secretion and
Ser101, Ser119,
IGFBP-1
cell media Phosphorylation Ser169
IGF-I bioactivity
P6 cell
IGF-1Rβ
Phosphorylation Tyr1135
lysate
Other
HepG2
Equal protein loading of
β-actin
and P6
Expression
N/A
cell lysates
cell lysate
Protein

A tabular representation of the various proteins assessed for expression and
phosphorylation in this manuscript, fractions assayed, phosphosites, and implications in
mTOR, AAR and IGFBP-1 regulation.
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Supplementary Figure 3. 1. Efficiency of CK2α+α’+β silencing. Representative
immunoblots of HepG2 cell lysates (50 μg per lane) demonstrateknockdown efficiencies
of CK2α+α’+β subunits. CK2α, CK2α’and CK2β expression were decreased (-45-55%)
regardless of leucine status in HepG2 cells treated with siRNA against all three CK2
subunits. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001
versus control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3. .
Sc:450: Scrambled siRNA, 450 μM leucine. Sc:0: Scrambled siRNA, 0 μM
leucine.CK2:450CK2 siRNA, 450 μM leucine. CK2:0: GCN2 siRNA, 0 μM leucine.
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Cell Vitality
(arbitrary units)
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Supplementary Figure 3. 2. HepG2 cell vitality after treatment with BIS (7.5 μM)
for 24 hours. A graphical representation of cell vitality between leucine plus or minus
treatments with or without BISs. A Trypan Blue exclusion assay was conducted to assess
cell viability, illustrated as the ratio of live to total cells. Values are normalized to
viability in control samples (leucine plus, no inhibitor). BIS inhibitor did not compromise
cell survival. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p <
0.001 versus control; One-way analysis of variance;
Dunnet’s Multiple Comparison Test; n=3. C: Control, 450 μM leucine. LD: Leucine
deprivation, 0 μM leucine. BIS: Bisindolylmaleimide (7.5 μM), 450 μM leucine. BIS:LD:
Bisindolylmaleimide (7.5 μM), 0 μM leucine.
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Supplementary Figure 3. 3. Efficiency of pan-PKC silencing. A representative
immunoblot of HepG2 cell lysates (50 μg per lane) assayed for PKCδ and PKCε
expression following siRNA silencing of pan-PKC. The expression of A. PKCδ and B.
PKCε were both reduced (-50%) regardless of leucine status by pan-PKC siRNA in
HepG2 cells.Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p <
0.001 versus control; One-way analysis of variance;
Dunnet’s Multiple Comparison Test; n=3. Sc:450: Scrambled siRNA, 450 μM leucine.
Sc:0: Scrambled siRNA, 0 μM leucine. PKC:450 pan-PKC siRNA, 450 μM leucine.
PKC:0: pan-PKC siRNA, 0 μM leucine.
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Supplementary Figure 4. 1. Dose-dependent changes in IGFBP-1 phosphorylation
with U0126. A significant decrease in IGFBP-1 phosphorylation was seen at 16µM
U0126 which remained consistent at approximately twice the inhibitor concentration (30
µM). A middle concentration between 5µM and 16µM U0126 (10 µM) was used in
subsequent experiments.Values are displayed as mean + SEM. *p< 0.05, **p= 0.0010.05, ***p < 0.001 versus control; One-way analysis of variance;
Dunnet’s Multiple Comparison Test; n=3.
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Supplementary Figure 4. 2. Dose-dependent changes in IGFBP-1 phosphorylation
with Bisindolylmaleimide (BIS). A significant decrease in IGFBP-1 phosphorylation
was seen at 10 µM BIS which remained consistent at twice the inhibitor concentration
(20 µM). A middle concentration between 5µM and 10µM BIS (7.5 µM) was used in
subsequent experiments.Values are displayed as mean + SEM. *p< 0.05, **p= 0.0010.05, ***p < 0.001 versus control; One-way analysis of variance;
Dunnet’s Multiple Comparison Test; n=3.
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Supplementary Figure 4. 3. Dose-dependent changes in IGFBP-1 phosphorylation
with PKI (5-24). PKI did not reduce IGFBP-1 secretion (i) or phosphorylation (ii-iv) in
basal conditions. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p
< 0.001 versus control; One-way analysis of variance;
Dunnet’s Multiple Comparison Test; n=3.
N.B. PKI (5-24) (IC50=22 nM)ahas been used in concentrations up to 2 µM in HepG2
cellsb. We used conservative doses of PKI to assess the ability of PKA to phosphorylate
IGFBP-1. As PKI was unable to diminish IGFBP-1 phosphorylation in basal conditions
at the assayed doses, we employed the maximal surveyed dose (100 nM) in our
subsequent assessment of IGFBP-1 phosphorylation in leucine deprivation.
a

de Boer AR, Letzel T, Lingeman H, Irth H. Systematic development of an enzymatic phosphorylation assay compatible with mass
spectrometric detection. Anal Bioanal Chem. 2005;381(3):647-655.
b
Citterio C, Jones HD, Pacheco-Rodriguez G, Islam A, Moss J, Vaughan M. Effect of protein kinase A on accumulation of brefeldin
A-inhibited guanine nucleotide-exchange protein 1 (BIG1) in HepG2 cell nuclei. Proc Natl Acad Sci U S A. 2006;103(8):2683-2688.
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Supplementary Figure 4. 4. Fibrinogen as a loading control in conditioned media.
Representative aliquots (30 μL) of HepG2 cell media from leucine plus and leucine
minus treatments, with and without the various inhibitors used in this study (TBB, PKI,
BIS, U0126), were probed with primary antibody against fibrinogen. Fibrinogen
secretion remained consistent among treatments regardless of total IGFBP-1 secretion
and IGFBP-1 phosphorylation.
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